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the most common form of monogenic diabetes, Maturity Onset Diabetes of the Young 3 (MODY3) caused
by heterozygous mutations in the transcription factor HNF1A. In this thesis research, we found that the lack
of HNF1A does not impair the generation of beta-like cells; Wild-type (WT) and mutant cell lines presented
similar differentiation efficiency between genotypes. HNF1A is necessary to repressed alpha cell fate; loss of
HNF1A leads skew beta-like cell differentiation towards alpha cell type. We also explore beta cell function
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secretion and cellular respiration leading to lower glycolysis metabolism and mitochondrial respiration. We
explore the HNF1A relationship between phenotype and genotype by generating a genome profiling analysis
of HNF1A. We MODY3 models confirmed that many of the genes that are dis-regulated in the Hnf1α mouse
model such us HNF4A, PCSK1, GC, DDP4, KIF12 6GPC2 and others. Besides, we also found a large
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family a novel long non-coding (lnc)RNA LINC01139. This lncRNA is only present in primates, and also it is
expressed in human endocrine cells. We interrogate the role of this lncRNA, and we found that it recapitulates
a subset of phenotypes seen in HNF1A, related with defects in glycolysis, mitochondrial respiration, and
downregulation of group of genes downstream of HNF1A. Our work offers a model to define the unique
biology of HNF1A in humans that may be distinct from rodent models leading to a better understanding of
human beta cell physiology with clinical implications for MODY3 patients but also with broader applications
to diabetes.
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ABSTRACT 
 
MODELING MONOGENIC DIABETES MODY3 USING HUMAN PLURIPOTENT STEM 
CELLS 
 
Fabian Leonardo Cardenas-Diaz 
Paul J Gadue 
 
Understanding monogenic diabetes has been challenging due to the lack of human 
model but also because mouse models do not recapitulate the disease. Here, we use 
human pluripotent stem cells (ESCs) and CRISPR-CAS9 (Clustered Regularly 
Interspaced Short Palindromic Repeat)/Cas9) nucleases to understand the most 
common form of monogenic diabetes, Maturity Onset Diabetes of the Young 3 (MODY3) 
caused by heterozygous mutations in the transcription factor HNF1A. In this thesis 
research, we found that the lack of HNF1A does not impair the generation of beta-like 
cells; Wild-type (WT) and mutant cell lines presented similar differentiation efficiency 
between genotypes. HNF1A is necessary to repressed alpha cell fate; loss of HNF1A 
leads skew beta-like cell differentiation towards alpha cell type. We also explore beta cell 
function related to insulin secretion and cellular bioenergetics; we found that HNF1A 
needs it for proper insulin secretion and cellular respiration leading to lower glycolysis 
metabolism and mitochondrial respiration. We explore the HNF1A relationship between 
phenotype and genotype by generating a genome profiling analysis of HNF1A. We 
MODY3 models confirmed that many of the genes that are dis-regulated in the Hnf1α 
mouse model such us HNF4A, PCSK1, GC, DDP4, KIF12 6GPC2 and others. Besides, 
we also found a large number of genes to be uniquely dis-regulated in the human model, 
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which could explain the species-specific phenotype. These genes include the 
transcription factors RFX6, GLIS3 and PAX4, the metallothionein gene family a novel 
long non-coding (lnc)RNA LINC01139. This lncRNA is only present in primates, and also 
it is expressed in human endocrine cells. We interrogate the role of this lncRNA, and we 
found that it recapitulates a subset of phenotypes seen in HNF1A, related with defects in 
glycolysis, mitochondrial respiration, and downregulation of group of genes downstream 
of HNF1A. Our work offers a model to define the unique biology of HNF1A in humans 
that may be distinct from rodent models leading to a better understanding of human beta 
cell physiology with clinical implications for MODY3 patients but also with broader 
applications to diabetes. 
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CHAPTER 1:  INTRODUCTION & OVERVIEW 
 
The hope of human stem cell research to model human diseases in vitro. Diabetes 
as a case study. 
 
Understanding the biology of the human disease is a challenge to the scientific 
community, not only because multiple factors might contribute to the complexity of the 
biology of the disease, but also because access to human tissues to perform 
experiments is limited. Our knowledge of human biology has been possible because 
different organism models such as Drosophila melanogaster, Caenorhabditis elegans, 
and Danio rerio, to name a few, have played an indisputable role in fundamental 
discoveries, helping us understand developmental processes and cellular mechanisms 
elemental to life. However, the evolutionary distance of these organisms to humans 
makes challenging to mirror human clinical pathophysiology and therefore limits their 
use in modeling certain aspects of human diseases and drug discovery (Alföldi & 
Lindblad-Toh 2013; Merkle & Eggan 2013; Avior et al. 2016). Rodents are a useful 
model to understand human diseases. They have provided insights into disease 
mechanisms, but still, display interspecies differences that make challenging to 
recapitulate fully human disease. For example interrogation of different gene variants 
has presented disparities in phenotypes between human and mouse. Heterozygous 
mutations in genes related with diabetes in human (HNF1A, HNF1B, HNF4A, GATA6 
and GATA4) do not phenocopy in mouse models (Merkle & Eggan 2013; Justice & 
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Dhillon 2016; Pontoglio et al. 1998; Weber et al. 1996; Rodríguez-Marí et al. 2011; Ryffel 
2001; Xin et al. 2006)  
 
The ideal scenario to dissect the biology of human disease requires the use of 
primary patients or their derived material. However, accessing human tissues and 
maintaining cells and tissues long term in the laboratory is difficult. Another source could 
be the generation of cells types of interest using human embryonic stem cells (ESCs) or 
induced pluripotent stem cells (iPSCs). 
 
The discovery ESCs and iPSCs, using our knowledge of developmental biology, 
makes possible to mimic the process of development with stepwise differentiation 
protocols to derive cell populations of clinical interest (Sauer et al. 2014; Murry & Keller 
2008; Mummery et al. 2012; Lim et al. 2013). The recent discovery of Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR) CAS9 nucleases, facilitates 
the correction or introduction of specific pathogenic mutations and makes possible the 
generation of isogenic cell lines and the examination of the same genetic variant in 
multiple genetic backgrounds (Cong & Zhang 2015; Bassett 2017; Zeng et al. 2016). 
ESCs and iPSCs have given an essential opportunity for biological research allowing us 
to answer questions that a few years ago were difficult due to the lack of a human 
model. 
 
Diabetes is one of the oldest known human diseases, characterized by disruption of 
glucose homeostasis as a consequence of abnormal insulin secretion and/or 
responsiveness.  The two most commons forms, type I and type II, are associated with 
eventual loss of insulin secretion, the beta mass cell, which can occur either early (type 
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I) or late in disease progression (type II) (Polonsky 2012; Bastaki 2005). Currently, more 
than 400 million people have diabetes, reaching epidemic levels because of the high 
number of people carrying the disease and also the high rate of mortality (Zheng et al. 
2017). It is relevant to understand the molecular mechanism of diabetes to control the 
epidemic of the disease. The third type of diabetes is monogenic diabetes, resulting in 
hyperglycemia because specific mutations in a single gene affect beta cell function in a 
cell-intrinsic manner (Kleinberger et al. 2017). Genome-wide association studies 
(GWAS) have identified different genes that cause monogenic diabetes as a risk factor 
for T1DM or T2DM (Voight et al. 2010; Fuchsberger et al. 2016; Jerram & Leslie 2017). 
Generation of beta-like cells derived from hESCs carrying mutations relevant to 
monogenic diabetes represents a valuable model, to understand the molecular 
mechanism of the disease pathogenesis and translate to other types of diabetes. 
 
The goal of this dissertation is to use hESCs to develop a human beta-like cell 
model, to study the role of the transcription factor hepatocyte nuclear factor one alpha 
HNF1A (HNF1A) that causes the most common monogenic diabetes in humans. My 
dissertation research focuses on using genetically manipulated ESCs to derive beta-like 
cells and immortalized human beta cell line (EndoC-BH1), both of which, carry mutations 
in the HNF1A gene. We use the CRISPR-CAS9 system to genetically modify ESCs to 
ablate one or two alleles of HNF1A. We combine the use of human in-vitro models along 
with functional assays and transcriptome analysis to understand the role of HNF1A in 
pancreatic development and beta cell function. Our data suggest that HNF1A plays an 
essential role in endocrine cell development and that loss of HNF1A led to an increase in 
alpha cell markers including glucagon and decreased expression of a critical 
transcription factor that regulates beta cell fate, PAX4. We also see impairments in 
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insulin secretion as well as metabolic defects in glycolysis and mitochondrial respiration. 
We found that the loss of a human-specific long non-coding RNA (lncRNA), LINKA 
explained a subset of HNF1A phenotypes,  as cells deficient for LINKA displayed similar 
defects in mitochondrial respiration. In overall, these studies highlight the importance of 
using a human model system to study endocrine cell development, beta cell function and 
disease in vitro. 
 
From endoderm to Pancreas  
    
 Most of the details of pancreas development come from the mouse model. This 
knowledge has been extrapolated to human development to establish in vitro 
differentiation protocols to generate endocrine cells from human ESCs or iPSCs. In 
mouse, during early embryo development around E6-7.5 end of gastrulation formed 
three germ layers ectoderm, mesoderm and endoderm all derived from the 
epiblast(Lewis & Tam 2006). These last two layers formed a common precursor called 
mesendoderm derived from the primitive streak (PS) where gradient concentration of 
Nodal signaling (TGFβ family) plays an important role to initiate the induction of the 
mesoderm and endoderm. High Nodal is present in the anterior region of the PS and 
promotes endoderm induction, and lower Nodal induces mesoderm (Dubrulle et al. 
2015; Zorn & Wells 2009). Wnt signaling maintains nodal expression, and it is crucial to 
induce gene expression of different transcription factors like Foxa2, Sox17, 
Eomesodermin, and Gata4-6 to induce endoderm and mesoderm lineages and 
regionalize the nascent endoderm (Zorn & Wells 2009; Pauklin & Vallier 2015). This 
structure can be divided into three different areas according to its location posterior or 
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anterior and includes the hindgut, midgut, and foregut. It is the foregut which will develop 
into the thyroid, esophagus, liver, stomach, lungs, and pancreas will develop (Figure 1.1)  
  
 
 
 
 
 
Figure 1.1. Endoderm development and endoderm-derived organs. Formation of the 
three main germ layer, mesoderm and endoderm derived form the mesendoderm. The 
endoderm will give rise to the primitive gut tube that become regionalized in foregut, 
midgut and hindgut. From the foregut different organs will be form between then 
pancreas, liver, lung, thyroid, esophagus, stomach. (Zorn & Wells 2009). 
    
Pancreas organogenesis in the mouse presents two transitions. The first 
transition happens from E9 to E12.5. At E9, there is evident thickening of the endoderm 
and formation of dorsal pancreatic bud 12 hours later in the ventral endoderm the 
emerge of the ventral pancreatic bud arises. Dorsal and ventral bud come from different 
signaling environments, where the dorsal bud experiences inhibition of sonic hedgehog 
and expression of retinoic acid (RA) and fibroblast growth factor (FGF) and the ventral 
pancreas receives signaling from the cardiac mesoderm (source of FGFs) and septum 
transversum mesenchyme (source of BMPs) (Pan & Wright 2011; Mastracci & Sussel 
2012; Benitez et al. 2012). Each bud has multipotent progenitor cells (MPC) expressing 
transcription factors such as Pdx1, Ptf1a and Sox9.T he buds actively proliferated, form 
stratified epithelium and multiple micro-lumens (Mastracci & Sussel 2012).  
 
Gastrulation Mesendoderm Endoderm Foregut
Ectoderm Mesoderm Midgut
Hindgut
! Pancreas
Lungs
Liver
Small intestine
Large intestine
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At E11.5, the gut starts to coil, and this rotation brings together the dorsal and ventral 
pancreas, and they fuse forming one structure. This new structure is a densely packed 
epithelium that continues growing building finger-like structures into the mesenchyme 
tissue. The most distal part of the finger-like structure is called the tip, and the basal area 
corresponds to the trunk. The tip domains have MPC that will give rise to endocrine and 
exocrine cells while the truck will produce endocrine and ductal cells (Benitez et al. n.d.; 
Joel F Habener et al. 2005). 
 The second transition occurs from E13.5 to birth, characterized by extensive 
epithelial formation and massive differentiation into endocrine, duct and acinar cells. The 
commitment of the endocrine cells presents the expression of Neurogenin3 (Ngn3). β 
and α-cells undergo expansion, and at E14-18 the endocrine cells start to aggregate 
along the duct and blood vessels and start forming the islets of Langerhans, which 
contain clusters of endocrine cells (Figure 1.2) (Cheng F & Wright C 2011). 
 
  
 
Figure 1.2. 
Pancreas organogenesis. Mouse pancreas organogenesis presents two different 
transitions. “Primary transition” is from E9.5 to E13 characterized by active cell 
proliferation and thickening of the endoderm which rapidly expands forming micro-
lumens with presence of expression of transcription factors like Pdx1 and Ptf1a, before 
E13 micro-lumens start branching forming finger-like structures with specific gene 
expression, Nkx6.1 expressed in the trunk and Ptf1a expressed in the tip.  “Secondary 
transition” start at E13 until birth, endocrine cell formation becomes compartmentalized 
forming islets like structures with an increase or branching structures. (Modified from 
Benitez et al. 2012) 
!!!!!!!!!!!!!!!!!!!!E8.5!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!E9.5!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!E11!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!E13!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!A*er!E13!!
TIP!
TRUCK!
P41a+!
Nkx6.1+!
Acinar!
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!
Duct!
Endocrine!
Islets!
Primary!transiGon! Secondary!transiGon!
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Endocrine pancreas  
Pancreas consists of exocrine, ductal and endocrine tissues. The exocrine tissue 
specified by the activation of Notch signaling which activates the expression of Hes1 and 
which inhibits Ngn3 expression (Afelik & Jensen 2013; Afelik et al. 2012). However, 
Ngn3 plays an essential role in pancreas development since it influences the expression 
of a diverse number of well-known transcription factors involved in pancreas 
development and beta cell function (Pdx1, Nkx6.1, Sox9, Nkx2.2, Neurod1, Ngn3, Pax4, 
Rfx6, Pax6, Glis3 and others)(Gasa et al. 2004). Ngn3 is a master regulator that will 
specify the endocrine pancreas where five cell types will be generated, and each cell 
type will secrete different types of hormones: α-cells secrete glucagon, β-cells secrete 
insulin, δ-cells secrete somatostatin, ε-cells produce ghrelin, and PP cell secrete 
pancreatic polypeptide (Figure 1.3)(Joel F. Habener et al. 2005; Sheets et al. 2018; 
Murtaugh 2006).   
 
Figure 1.3. Pancreatic 
endocrine specification. 
Delineation of the different 
cell types that are found in 
the pancreatic endocrine 
islet, depicting the various 
transcription factors that are 
known to be required to 
specify each cell type 
(Modified from Murtaugh 
2006) 
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α-cell
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While the generation of each of the endocrine cell populations from Ngn3+ cells is still a 
matter of active research, it is known that counteracting transcriptional networks induces 
α-cell and β-cells. Arx and Pax4 are two transcription factors that repressed each other 
and help define the alpha versus beta cell populations. Arx drives the α-cells formation, 
and Pax4 transcription factor is critical for β-cells formation (Collombat et al. 2005; 
Kordowich et al. 2012). 
  
The endocrine population of the pancreas becomes organized into small 
structures or mini-organs called islets of Langerhans. The average size of an islet is 
108µM, and a human pancreas can have between 3.2 to 14.8 million islets with a total 
volume of 0.5 to 2.0 cm3, which represents 1 to 2% of the pancreas (Da Silva Xavier 
2018; Ionescu-Tirgoviste et al. 2015). The Islets of Langerhans are highly vascularized 
structures; they have five times more capillaries than exocrine pancreatic tissue and 
receive 5-15% of the entire pancreatic blood flow even though they consist of only 1-2% 
of the pancreatic mass (Ballian & Brunicardi 2007). Islet architecture varies between 
species with striking differences seen when comparing human and mouse islets. In the 
mouse, the inner core of the islet is mainly β-cells and is surrounded for α-cells and δ-
cells, while in humans the cells scattered throughout the islet. Another difference is the 
proportion between α-cells and β-cells between mouse and human. Mouse islets 
average cell composition is 77% β-cells, 18% α-cells whereas in human is 55% β-cells, 
38% α-cells (Cabrera et al. 2006; Dolen & Rupnik 2015) 
 
These differences in islet structure between species have been showing to have 
an impact in islets physiology related with calcium flux. Comparisons of β-cells calcium 
oscillations demonstrate that mouse presented coordinated oscillations due to β-cells in 
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the mouse are highly condense in a core structure, but this did not seem in human β-
cells. (Cabrera et al. 2006) There are other functional differences between human and 
mouse islets related with β-cells metabolism in glycolysis, mitochondrial function and the 
ability of mouse β-cells to compensate metabolic dysfunction by adjusting β-cell glucose 
sensitivity (MacDonald et al. 2011; Gregg et al. 2016)  
       
Pancreatic β-cells regulates blood glucose homeostasis 
Islet of Langerhans represent a small proportion of the pancreatic cells, but they play a 
significant role regulating blood glucose homeostasis because they are the home of the 
pancreatic hormone β-cells (produce insulin) and α-cells (produce glucagon). 
 α and β-cells cells regulate blood glucose homeostasis concentrations to close 
to 100mg/dl (5mM) glucose. When blood glucose becomes low, glucagon is secreted 
from alpha cells to promote gluconeogenesis from the liver to reestablish glucose 
homeostasis (Gelling et al. 2003). Increase in glucose above 6mM in the bloodstream 
due to food intake will lead to insulin secretion from beta cells and stimulate the glucose 
uptake from muscle and adipose tissues via the insulin-dependent glucose transporter 
(Röder et al. 2016; Fu et al. 2013). Maintaining a tight blood glucose range can only 
occur because beta cells can monitors changes in blood glucose levels. When glucose 
increases, glucose is taken up in the beta cells via glucose transporters Glut2 in mouse, 
GLUT1, and GLUT3 in human (McCulloch et al. 2011). Glucose is transformed into ATP 
via glycolysis and this increases in ATP will change intracellular ATP/ADP ratio, 
mediating the closure of K+ATP dependent channel and resulting in the opening of 
voltage-dependent Ca+ channels. The increase in cytosolic Ca+ will, in turn, activate the 
release of insulin stored in insulin granules. This process occurs by fusion of the 
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granules to the cellular membrane via synaptosomal-associated proteins (Figure 1.4) 
(Torrejón-Escribano et al. 2011; Röder et al. 2016)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Glucose stimulation insulin secretion  (GSIS) in pancreatic beta cells. 
Increase in blood glucose will increase the uptake of glucose using the glucose 
transporter in beta cells, then glucose is metabolized into ATP, increase concentrations 
of ATP alters ATP/ADP ration depolarizing beta cell membrane and leading to an 
increase in intracellular calcium, this increase cause insulin granules fuse to cellular 
membrane released from the cell 
       
 
Forms of diabetes 
Diabetes is one of the oldest diseases in human history. Indian texts dated from 
the 5th century BC describe people with symptoms of polyuria and very thirsty. 
Diagnosis of diabetes was based on tasting the urine, as patients with this disorder 
would excrete glucose in the urine. In 1674, Thomas Willis coined the name diabetes 
mellitus, when he tasted dried urine from diabetic patients and described it as sticky and 
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similar taste to honey (quasi melle) (Eknoyan & Nagy 2005). Diabetes mellitus is rapidly 
becoming one of the largest and most expensive risks to global public health (Chan & 
Luk 2016; Whiting et al. 2011). Currently, approximately 9% of the world population has 
some form of diabetes, and this prevalence is projected to continue to increase 
(Wareham & Herman 2016). In 2017 alone, treatment costs related to diabetes in the 
United States rose to 327 billion dollars (Wenya Yang, Timothy M. Dall, Kaleigh Beronjia 
. Janice Lin, April P. Semilla, Ritashree Chakrabarti 2018). Unfortunately, diabetes has 
significant associated mortality, ranking as the sixth leading cause of death in the world 
and contributing to the mortality of other conditions such as cardiovascular and renal 
disease (Ashcroft & Rorsman 2012; Ali 2013; Zheng et al. 2017). Diabetes mellitus 
results from impaired insulin secretion or action, or both, resulting in high serum glucose 
levels (Seino et al. 2011). Despite decades of research, our understanding of the 
underlying pathogenesis of diabetes, especially pancreatic β-cell dysfunction, remains 
incomplete. Diabetes in all forms has a strong genetic component with the use of 
strategies such as genome-wide association studies (GWAS) in the past decade have 
helped discover candidate genes that are important in β-cell physiology and 
pathophysiology (Billings & Florez 2010; Voight et al. 2010; Fuchsberger et al. 2016)  
 
Type one diabetes mellitus (T1DM) 
 During type one diabetes mellitus, autoimmune destruction of the beta cells 
results in hyperglycemia. T1DM cases account for 10% of the diabetic population, and it 
is the most common form of diabetes in children <15 years of age. 90000 children are 
diagnosed every year, and currently, 542000 children are suffering from T1DM (Figure 
1.6) (Diaz-Valencia et al. 2015)  
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The T1DM present antibodies against some beta cell antigens, such as glutamic 
acid decarboxylase (GAD65), insulinoma-associated protein 2 (IA-2) or zinc transporter 
8 (ZNT8) can be detected months or years before symptoms of hyperglycemia (Krischer 
et al. 2015). For T1DM to occur a genetic predisposition must exist in combination with 
environmental factors will trigger immune attacked of beta cells. The early phase is 
asymptomatic as the pancreas has an excess of beta cells. Auto-antibodies can be 
detected in this stage, with glucose homeostasis being lost the only result upon loss of a 
significant mass of beta cells (Figure 1.5) (van Belle, T.L., Coppieters, K.T. & von 
Herrath 2011)  
 
 
 
 
Figure 1.5. A linear model to 
describe beta cell decay in type 
1 diabetes. Beta cell mass is 
intact before and environmental 
factor triggers autoimmune 
antibodies an at some time 
(months or years) beta cell mass 
decreases dramatically that insulin 
or C-Peptide are barely detected, 
and the islet cannot regulate blood 
glucose homeostasis resulting in 
hyperglycemia.(Modified from van 
Belle, T.L., Coppieters, K.T. & von 
Herrath 2011 and Katsarou et al 
2017) 
 
 
The pathogenesis of T1DM and its molecular mechanism underlying this disease 
is unclear, but it is known that autoantibodies reflect autoantigen presentation by 
dendritic cells and the subsequent responses of autoantigen-specific CD4+ and CD8+. T 
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advanced T1DM, recognize post-translational modified peptides specific to beta-cells 
(Katsarou et al. 2017).  
 
It is uncertain how T1DM is triggered, but after more than four decades of 
research,  different aspects are considered from genetics to environment.  First, T1DM is 
a polygenic disease where genetic factors are necessary but not sufficient to cause the 
disease. There is a concordance rate of 30-50% in Monozygotic twins and 6-10% in 
zygotic twins, an individual with a first degree relative with T1DM have a risk of 1 to 20, 
and the general population is the 1 to 300, indicating the influence that genetics plays 
while also demonstrating that even in a permissive genetic background disease is not 
100% penetrant  (Atkinson 2012). There are around 50 loci associated with the 
susceptibility to develop the disease, with the Human Leukocyte Antigen (HLA) providing 
the most substantial contribution of approximately 60% contribution HLA genes encode 
for molecules that participle in antigen presentation and it is thought that HLA 
predisposes disease by presenting specific autoantigens. Other loci are under research 
to gain new insights into genetic risk and autoimmunity (Concannon et al. 2009). 
 
 The environment is another component to consider in the T1DM field. Different 
hypotheses are proposed, such as the accelerator or overload hypothesis suggest 
stressors in the environment will cause the beta cells to over-work, leading to exhaustion 
and beta cell damage which trigger the immune response. The hygiene hypothesis 
states that prevalence of the disease will be higher in countries where continuous 
improvement in sanitation and living standards predispose to the disease by allowing 
underused components of the immune system to attack itself (Kondrashova et al. 2013). 
The fertile field hypothesis claims that microbial infection with antigens cross-reactive to 
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autoantigens may yield the autoreactive T cells (Coppieters et al. 2012). Another 
hypothesis called North-South Gradient is based on the observation that the highest 
incident of T1DM is in North European countries, suggesting that low serum vitamin D 
could be associated and contributing to the development of the disease (soltész 2009; 
Hyppönen et al. 2001). To conclude, T1DM predominantly occurs in children <15 years 
old, the genetics of the disease is still quite complicated, and several environmental 
factors need to be present to trigger the immune reaction and target beta cell 
destruction, which eventually will lead to hyperglycemia. 
 
Type two diabetes mellitus (T2DM),  
 
This type of diabetes presents impaired insulin secretion, insulin resistance or 
both, as well as chronic inflammation, which disrupts blood glucose homeostasis 
(DeFronzo et al. 2015; Ali 2013). T2DM accounts for 90% of the reported diabetic cases, 
which are around 400 million adults that range from 20-70 years old (Zheng et al. 2017). 
Epidemiological studies show that T2DM has an active component associated with, i.e., 
sedentary behavior, lack of sleep or oversleeping and smoking cigarettes increases the 
chances of developing the disease. Additionally, genetics play another role that needs to 
be added to the equation for the development of T2DM (DeFronzo et al. 2015). 
 
 Heritability of T2DM from twins studies has been shown to be from 20-80% 
depending on the population examined. The risk to develop T2DM in a lifetime is 40% 
for individuals with one affected parent and the chances increases to 70% when both 
parents have it (Ali 2013). Genome-wide association studies (GWAS) have also been 
used to identify risk genes associated with T2DM. The number of common variants 
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identified is around 100 genes, related with obesity (FTO, MC4R), cyclin-dependent 
kinase (CDKAL1, CDKN2A, CDKN2B), transcription factors associated with beta cell 
function and pancreas development  (NEUROD1, HNF4A, HNF1A, TCF7L2, 
HHEX,PTF1A, PAX6, PAX4), ion channels ( SLC30A8, SLC16A1) and others (Ali 2013; 
Fuchsberger et al. 2016). From these studies, the majority of heritability cannot explain 
the currently identified risk allele variants. It could be due to disease heterogeneity, 
gene-environment interactions, and possible epigenetic mechanisms. 
 
 Characterization of beta cells in T2DM show multiple factors that can contribute 
to beta cell failure possibly due to cellular exhaustion and prolonged exposure to 
hyperglycemia and include cell dedifferentiation, abnormal beta cell respiration and 
finally apoptosis. Studies using cadaveric T2DM islets have shown a reduction in insulin 
secretion in response to glucose stimulation, demonstrating that the cells in late-stage 
disease have problems with the secretory apparatus or glucose sensing (Deng et al. 
2004; Guillausseau et al. 2008). Another phenomenon observed in T2DM islets is the 
reduction in beta cell mass which could be due to the chronic stress including glucose or 
lipid toxicity and finally apoptosis. Another factor that could contribute is chronic 
inflammation as the presence of inflammatory cytokines or chemokines like IL-1B could 
lead beta cell dead (Marzban 2015). However,  alpha cells increase in prevalence in 
T2DM patients. This increase could be due to misregulation in gene expression in genes 
essential to maintain beta cell function and fidelity such as PDX1, MAFA, and NKX6.1, 
which experimental setting can lead to glucagon upregulation (Spijker et al. 2015; 
Spijker et al. 2013; Cho et al. 2011) To conclude, T2DM results in hyperglycemia 
predominant in a population >20 years old, where the pathophysiology of the disease 
includes insulin resistance and loss of beta cell function along with beta cell mass. 
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Additionally, T2DM presents a combination of genetic predisposition with different 
environmental factors such as lack of physical activity and high carbohydrate diet.  
  
Monogenic Diabetes 
 This type of diabetes is due to mutations in a single gene, typically related to beta 
cell development or beta cell function. Monogenetic diabetes is classified in two 
categories: Neonatal diabetes mellitus (NDM) or Maturity onset of the young (MODY) but 
to organize the mutation as monogenic diabetes they must display a dominant form of 
inheritance and lead to the onset of disease below 25 years of age.  
 
 Neonatal diabetes mellitus (NDM) is a rare type of diabetes that occurs in the 
first six months of life with an incidence of 1 in 160000 live births. Usually, the mutation 
occurs in genes related with pancreas development, insulin regulation or apoptosis. 8 
different genes have been identified in NDM (IPF1, EIF2AK3, GCK, FOXP3, KCNJ11, 
ABCC8, PTF1A and GLIS3) (Hattersley & Patel 2017; Ashcroft & Rorsman 2012; 
Harries et al. 2006). The most common NDM is activating heterozygous mutation in 
ABCC8 and KCNJ11. These genes encode for the K ATP channel in beta cells, which is 
an octameric protein structure with four KIR6.X subunits forming the channel pore. The 
pore surrounded by four sulfonylurea receptors (SURs) that regulate the channel pore 
activity. The unique sensitivity to ATP/ADP level changes induced by glycolysis makes 
this channel a metabolic cell sensor regulating insulin secretion (Hattersley & Patel 
2017). The KATP promotes insulin secretion, in their open state K+ ions efflux to 
maintain the cell membrane polarized so when there is a change in ATP/ADP ratio the 
cell KATP channel close the pore and cell membrane depolarized triggering the influx of 
calcium releasing insulin granules (Quan et al. 2011). Activating heterozygous mutation 
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in ABCC8 or KCNJ11 reduces the ability of metabolically generate ATP to close the 
channel preventing glucose-induced electrical activity and insulin release resulting in 
NDM (Ashcroft et al. 2017) 
  
 Maturity onset diabetes of the young (MODY) is the most common form of 
monogenic diabetes, 1-2% of the total diabetes cases reported. MODY is characterized 
by heterozygous mutations in a single gene involved in the fetal development of the 
pancreas or regulation of maturation and maintenance of beta cell function. In 1970’s 
this type of diabetes was present in patients with mild or no disease progression and it 
did not require insulin for treatment but in the 1990s the molecular characterization of 
different MODYs was revealed and since then more MODY genes have been discovered 
(TABLE 1.1).  
Table 1.1.  MODY subtypes and its clinical implications. 11 different form of MODY 
describes until now, and each MODY has its etiology based on its mutated gene. 
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MODY TYPE    GENE LOCUS                               CLINICAL FEATURE 
HNF4A        
GCK
HNF1A
IPF-1
HNF1B
NEUROD1
KLF-11
CEL
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Hyperinsulinemia        
Fasting hyperglycemia 
Defects insulin secretion
Moderate to severe β-cell dysfunction 
Progresive diabetes, exocrine defects
Moderate to severe β-cell dysfunction 
Pancreatic atrophy
Variable diabetes. Exocrine insufficiency
Ketosis prone to diabetes
Diabetes wide clinical exprectrum
Obesity
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MODY3, Hepatocyte Nuclear Factor One Alpha (HNF1A).  
 MODY3  is the most common of the MODYs, and mutations cause it in the 
transcription factor Hepatic Nuclear Factor alpha 1 (HNF1A). More than 400 
heterozygous mutations are reported along the exons, and the promoter is causing 
haploinsufficiency or dominant negative forms of the gene (Figure 1.6) (Colclough et al. 
2013; Ellard 2000; Harries et al. 2006; Yamagata 1996). Patients carrying heterozygous 
mutations in HNF1A present β-cell dysfunction and hyperglycemia. Diabetes is due to 
insufficient insulin release in response to a rise in glucose blood levels, suggesting that 
HNF1A heterozygous mutation impairs the function of pancreatic β-cells. (Byrne et al. 
1996). Significant efforts are made in understanding the physiology of the MODY3 
(Fajans & Bell 2011). However, the molecular mechanism by which MODY3 is triggers 
diabetes has been poorly studied due to the difficulty of obtaining patient samples and 
maintaining pancreatic β-cells in culture (Skelin et al. 2010).  
 Mouse models have been regularly used to understand the MODY3 disease. 
However, mice with heterozygous mutations in the HNF1α gene do not display any 
pathological phenotype (Pontoglio et al. 1998). HNF1α knockout (KO) mice or mice 
expressing a dominant negative version of HNF1α can present with hyperglycemia due 
to poor development of the pancreas, impaired in insulin secretion and abnormal gene 
expression of genes related to β-cell function such as glucose transporter 2 (GLUT2), 
mitochondria metabolism and also loss of β-cell mass by apoptosis (Bonner et al. 2010; 
D’Angelo et al. 2010; Wobser et al. 2002). Evidence suggests that HNF1A regulates 
insulin transcription and genes with roles in β-cell replication (Akpinar et al. 2005; Wang 
et al. 1998). Considering that these findings are based on mouse models which do not 
entirely mimic the MODY3 phenotype in humans, it is possible that there are human-
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specific roles for HNF1A (Bjørkhaug et al. 2003; Gragnoli et al. 1997). Several factors 
could explain this discrepancy between human and mouse. First, GLUT2 is not the 
principal glucose transporter in human β-cells. Second, the insulin gene has different 
regulatory sequences in mice and humans, and third, β-cell proliferation is regulated by 
different cell cycle genes in mice and humans (Hay & Docherty 2006; Matsui et al. 2012; 
Vos & Heimberg 1995; Odom et al. 2007). Therefore, a more suitable model for 
dissecting MODY3 pathogenesis and underlying HNF1A gene function in humans is 
needed, 
            
Figure 1.6. HNF1A gene structure and heterozygous mutations. HNF1A gene 
presents ten exons, encoded for a transcription factor protein with 632 amino acids. 
Protein structure presents three segments: 1-32aa dimerization domain, 150-278 DNA 
binding domain, and the 281-631 transactivation domain. 414 heterozygous mutations 
are reported along the gene but not homozygous mutations. Modified from Yamagata K. 
2014 
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Human Embryonic Stem Cells (ESCs) 
  
 Embryonic stem cells (ESCs) have two main characteristics that make them 
unique, they self-renew and also they are pluripotent. These two characteristics allow an 
unlimited source of cells that can give rise to all somatic lineages (Martello & Smith 
2014). Stem cells are found in the inner cell mass (ICM) at the blastocyst stage. The first 
mouse ESCs were isolated in 1981 using mouse embryos in diapause, which is a state 
where the embryo arrests as a consequence of estrogen deprivation.  Diapause 
facilitates the isolation of ICM, and the isolated cells were placed in conditions that 
promote cell survivor and proliferation by using mouse fibroblast feeder cells (Evans & 
Kaufman 1981; Martin 1981). In 1998, human ESCs were isolated from blastocyst 
donated from in vitro fertilization generated embryos for clinical purposes but were no 
longer needed. The isolated cells were cultured, and the first five human ESC cells lines 
were made (H1, H13, H14) with XY genotype and (H7, H9) with the XX genotype. The 
derived human ESCs can be passage for more than six months and still replicate and 
expressed cell surface markers specific for stem cells like stage-specific embryonic 
specific embryonic antigens while maintaining the ability to differentiate into derivatives 
of the three embryonic germ layers(Thomson 1998). There are now hundreds of human 
ESC lines that are available. 
 
 Even though ESCs have great potential to be used in biological research to 
understand fundamental biological processes, it presents some limitations in future 
therapeutic setting due to the same rejection problems that face current organ 
transplants.  Also, there are ethical concerns from individual members of society to use 
human embryos for research purposes (Dusko Ilic 2016; King & Perrin 2014) 
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Induce pluripotent stem cells (iPSCs) and disease  
 
 In 2006, Takahashi K & Yamanaka S. reported the generation of the first induced 
pluripotent stem cells (iPSCs), where transduction of four transcription factors (Oct3/4, 
Sox2, c-Myc, and Kif4) in mouse fetal fibroblast, demonstrating that somatic cells 
reprogrammed to a pluripotent stage IPSCs. The iPSCs created present the features of 
ESCs which allowed to used them to differentiate into different cell types. One year late 
after that discovery, different laboratories demonstrate similar findings and the 
technology to generate iPSCs in a laboratory is nowadays a standard procedure that 
replicates in many laboratories around the world (Nagaria et al. 2016; Wernig et al. 
2007; Maherali et al. 2007). Currently, iPSCs technology allows the generation of 
pluripotent cells from virtually any human, and protocols are being developed to 
differentiate those cell lines into many of the cell types found in the body.   IPSCs are 
being used to interrogate the role of the genetic variants in disease pathogenesis in 
multiple derivative cell types including pancreatic beta-like cells, different types of 
neurons (Jaiswal 2017; McKinney 2017), cardiomyocytes (Masumoto et al. 2014; 
Mummery et al. 2012), hematopoietic stem cells (Lim et al. 2013; Lachmann et al. 2015), 
hepatocytes (Sauer et al. 2014) , intestinal organoids (Takahashi et al. 2018) and others. 
This system is being used to better understand many genetic diseases including 
diabetes, Alzheimer disease, long QT syndrome, and others. IPSCs are a useful tool 
used for personalized medicine where differentiated cells with specific phenotype are 
being used for drug screening platforms to find a particular compound that helps to 
improve a patient-specific phenotype. For example, a polymorphism in the KCNH2 
channel causes arrhythmias in a patients that using the conventional drug therapy 
formulation did not correct the defect but after using iPSC derived cardiomyocytes 
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derived from the patient allowed investigators to perform a series of drug screens and 
find the appropriate compound to fix the arrhythmias caused by the mutation (Terrenoire 
et al. 2013). Moreover, iPSCs have been used in clinical trials and are being considered 
for clinical trials that could lead to treatments of spinal cord injury, macular degeneration, 
diabetes, heart disease and others (Dusko Ilic 2016; Mandai et al. 2017). 
 
Generation of derived beta-like cells 
 Start with the introduction to in vitro differentiation in general. Different step-wise 
differentiation protocols have been established to generate human beta-like cells.  
Protocols to generate insulin+ (INS+) beta-like cells utilized the knowledge acquired from 
mouse endoderm and pancreas specification and translated this information into the in 
vitro system. The use of ESCs with cytokines and small molecules that mimic 
developmental signals can be used to pattern the ESCs to the endoderm germ layer, 
and subsequently into pancreatic progenitors and INS+ cells (Ma et al. 2017; Bruin et al. 
2014). However, early protocols generated INS+ cells with a high percentage of cells co-
expressing other hormones along with insulin (polyhormonal cells) that did not respond 
to glucose challenge. This polyhormonal population is a phenomenon observed during 
early development in both mouse and humans but these cells are not seen in adults of 
either species (Jeon et al. 2009; Riedel et al. 2012; Bruin et al. 2014), suggesting that 
the early protocols were generating a non-functional fetal population  of endocrine cells. 
Alternatively, transplantation of differentiated ESCs at the pancreatic progenitor stage 
into an immune-deficient mouse, the transplanted cells will mature into functional beta 
cells and can rescue diabetes a mouse model (Rezania et al. 2012). The most recent 
protocols published generate functional beta-like cells in vitro, with the generation of 
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INS+ cells that express NKX6.1 transcription factor and a reduction in polyhormonal cells 
(Pagliuca et al. 2014; Rezania, Bruin, et al. 2014). The cells generated in vitro, while 
displaying some glucose responsiveness, still exhibit an immature phenotype with much 
poorer functionality compared to adult primary human islets.   
 
Tools to assess beta cell function 
 Pancreatic beta cells upon activation with secretagogues such as glucose will 
undergo a signaling cascade that will ultimately drive an increase in intracellular calcium 
which in turn induces insulin granule fusion with the plasma membrane and secretion. 
To assess beta cell function, two common readouts for functionality are to measure 
calcium flux and insulin secretion. Current methods to examine both of these cellular 
activities have caveats that hamper either experimental design and/or throughput.  The 
following sections will highlight some novel tools used to monitor calcium flux and insulin 
secretion that overcome these difficulties.   
 
Preproinsulin-Gaussian-luciferase fusion protein 
 Secretion of insulin granules is usually measured using ELISA assays to detect 
C-peptide or Insulin. ELISA is a very useful and precise assay, but the main 
disadvantage of the procedure is the cost and time necessary to perform the test. The 
high cost per sample makes the C-Peptide ELISA prohibitive for large-scale 
experiments. Different alternatives have been described to measure insulin secretion in 
an affordable and high-throughput format. One method is to generate a fusion protein 
between insulin and Gaussian luciferase gene close to the C-Peptide portion of the 
prohormone. When preproinsulin protein is processed and cleaved the Gaussian 
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luciferase protein is included in the insulin granules and luciferase will be secreted along 
with insulin. Luciferase activity can then be used as a surrogate to quantify insulin 
secretion (Burns et al. 2015; El Ouaamari et al. 2013; Kalwat et al. 2016). As a proof of 
principle Burns et al. 2015 used a mouse beta cell line and showed that insulin-Gaussian 
luciferase is present at a ratio of 1:1 between insulin and luciferase in granules. 
Comparisons between insulin and luciferase secreted into the medium upon stimulation 
maintain this 1:1 correlation and demonstrate that luciferase activity accurate surrogate 
for insulin secretion.  Luciferase activity is also highly sensitive and can be used to 
perform high-throughput drug screening to study molecules that stimulate insulin 
secretion. 
 
Calcium flux and a measure of beta cell functionality  
 Another way to measure beta cell functionality is by measurement intracellular 
calcium flux under different stimuli. Commonly, a perfusion experiment is used where 
medias containing different stimuli are introduced to beta cell cultures under constant 
flow conditions (Hivelin et al. 2016; Kaminski et al. 2012). Measurements of intracellular 
calcium can be performed using two classes of Ca2+ indicators, cell permeable calcium-
dependent fluorophores, and genetically encoded protein calcium sensors.  While cell 
permeable calcium dyes are used to measure calcium flux, they also present some 
disadvantages. First, the calcium signal is not specific to a specific cell type, requiring 
the use of additional markers when studying heterogeneous cultures (Nakai et al. 2001). 
Second, the imaging equipment necessary to measure calcium dyes is somewhat 
complicated and requires very specialized microscope setups (Paredes et al. 2008). 
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 A solution for these issues related to using calcium dyes is genetically encoded 
calcium indicators such as GCaMP6. This protein indicator can be used to quantify 
intracellular calcium in a specific cell type due to GCaMP6 can be expressed under a 
particular type of cell promoter (Yang et al. 2018; Yin et al. 2014). Another essential 
feature of GCaMP6 is as a single-fluorescent protein-based indicator, and the excitation 
wavelength corresponds to one of the absorption maximum peaks of the indicator, which 
facilitates the fluorescence measurement using a standard epi-fluorescent microscope 
(Akerboom et al. 2009). Green fluorescence protein/Calmodulin protein sensor (GCaMP) 
has a variant of enhanced GFP fused to the calcium-binding protein calmodulin (CaM) 
and the CaM-binding protein M13pep (Sun et al. 2013). In the presence of high Ca2+ 
concentration the conformational change of the GFP protein induces a bright GFP 
signal, but with low Ca2+ levels GFP becomes less intense  (Nakai et al. 2001; Sun et 
al. 2013). Several groups have demonstrated that GCaMP6 is a reliable tool to quantify 
changes in Ca2+ using different genetic models such as Xenopus, Zebrafish, mouse 
and various cell lines  (Cai et al. 2014; Chen et al. 2012; Partridge 2015; Grienberger & 
Konnerth 2012; Huang et al. 2015). 
  
Overview of this dissertation 
            In this dissertation, our goal was to generate human pancreatic beta-like cells 
from ESCs to interrogate the role of HNF1A the most common gene in monogenic 
diabetes. We also validated our results by using a human immortalized beta cell 
(EndoC-βH1).  
In the following chapter (Chapter 2) we used ESCs from two different genetic 
backgrounds that were genetically manipulated using CRISPR-CAS9 nucleases to 
generate heterozygous and knockout cell lines of the HNF1A gene. A similar approach 
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was used to generate an HNF1A knockout in EndoC-βH1 cell line. ESCs were 
differentiated up to beta-like cell stage using the most recent pancreatic protocols. The 
establishment of this system allows interrogating the molecular mechanism of the 
pathogenesis caused by the deficiency of HNF1A. We used a series of experiments to 
answer specific questions related with beta cell differentiation and cell fate, beta cell 
function by insulin secretion and cell respiration and finally genomic profiling of HNF1A 
to look for the molecular targets involved in the phenotype of HNF1A. We found that 
deficiency of HNF1A leads to an increase of alpha cell gene expression and generation 
toward alpha cell-like population. The generated cells present impaired insulin secretion 
with defects in glycolysis and oxygen consumption where more than 500 genes could 
contribute to the phenotype. In particular, we characterized a lncRNA that explains a 
subset of HNF1A phenotypes related to oxygen consumption. 
In chapter 3, we used an EndoC-βH1 human immortalized beta cell line to generate 
molecular tools that allow the efficient quantification of insulin secretion and calcium flux. 
Utilizing the advantage to maintain in culture an immortalized beta cell, we asked the 
question if it is possible to generate a system that permits the simultaneous 
quantification of insulin secretion and calcium flux. Our approach was to create a 
lentivirus vector carrying the transgene to generate the fusion protein preproinsulin-
Gaussia luciferase (measure insulin secretion) and GCaMP6s (measure calcium flux). 
We were able to create a cell line that allows the quantification of insulin and calcium 
under different stimuli.    
            Finally, we discuss future directions and approaches that could be followed to 
answer in more detail the molecular mechanism of HNF1A regulating beta cell and how 
its deregulation can lead to a diabetes phenotype. We expect that the data showed here 
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contributes to a better understanding of the role of HNF1A in beta-like cells in vitro and it 
can help as an open discussion to use similar analysis to explore phenotypes related to 
diabetes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  28	  
CHAPTER 2. MODELING MONOGENIC DIABETES CAUSED BY MUTATIONS IN 
HFN1A IN HUMAN ES CELLS REVEALS DEVELOPMENTAL AND METABOLIC 
DEFICIENCIES. (Adapted From Paper) 
 
SUMMARY 
Studying monogenic diabetes, caused by a mutation in several genes essential in beta 
cell development and function, has been challenging due to multiple mouse models not 
recapitulating the human disease. Here, we use genome edited human ESCs to 
understand the most common form of monogenic diabetes, MODY3, caused by a 
mutation in the transcription factor HNF1A. We found that loss of HNF1A does not impair 
the generation of beta-like cells, but it is necessary to repress an alpha cell expression 
signature, maintain beta cell function, and impacts cellular metabolism. Also, we 
identified an HNF1A target, the human-specific long non-coding RNA LINKA, related 
with for normal cellular respiration in beta-like cells. These phenotypes give a possible 
cause for the species differences in phenotypes from HNF1A mutations as well as offer 
mechanistic insights into how HNF1A can influence its known role in type II diabetes. 
METHODS 
Cell Culture  
We used two different genetic backgrounds of stem cells: MEL1 and H1 hESCs, these 
cell lines were culture on 0.1% gelatin and irradiated mouse embryonic fibroblast 
(MEFs). The medium use to maintain cell growth and stemness was DMEM/F12 
supplemented with 2mM of glutamine, 15% Knockout Serum Replacement (KSR), 1X 
NEAA, 0.1mM β-mercaptoethanol and 10ng/ml of bFGF which we called hESC media. 
Cell were split when they reach 80% confluence using TrypLE and replate using 1/6 
ratio. 
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Pancreatic differentiation protocol 
Cells were incubated with accutase solution for 6 min at 37°C, cells were transfer to a 
50ml falcon tube washed twice using 40ml of DMEM-F12. 5.5 million cells were 
resuspended in 5ml of hESC media with 1µM of ROCK inhibitor and plate them on one 
well of 6-well plate of ultra low attachment cell culture plate. Plate was place on orbital 
shaker set up at 100rpm inside of incubator with 5% CO2 and 37°C. Overnight cells form 
embryoid bodies, which were fed for two days using hESC media. After two days, media 
was removed and it was replace with pancreatic differentiation media for day cero. 
During differentiation protocol until day 14, media was replace every 24 hours with fresh 
media made during the day. After day 14 cells were fed every day after with fresh media. 
 
Day cero media contains RPMI supplemented with 0.3mM Chir99021, 100µg/ml Activin 
A and 0.2% fetal bovine serum (FBS). For day 1 media contains RPMI with 100µg/ml 
Activin A, 0.03mM Chir99021, 10µg/ml bfgf and 0.2% FBS. For day 2 and 3 the 
backbone media was SFD with 100µg/ml Activin A. From day 4-6 the backbone  media 
was change to DMEM-F12 with 50ng/ml FGF7. Then media was replace from day 7-8 
with DMEM high glucose (5g/L) supplemented  with 1:100 B27 without RA, 1X glutamax, 
0.25mM ascorbic acid, 1:200 ITS-X, 50ng/ml FGF7, 0.5µM SANT-1, 1µM Retinoic Acid, 
100nM LDN-193189  and 500nM Phorbol. Media for day 9-11 consist of DMEM high 
glucose (5g/L) supplemented with 1:100 B27 without RA, 1X glutamax, 0.25mM ascorbic 
acid, 1:200 ITS-X, 2ng/ml FGF7, 0.5µM SANT-1, 0.1µM Retinoic Acid, 200nM LDN-
193189 and 250nM Phorbol. From day 12-14 the backbone media was change to 
MCDB131 supplemented with 20mM glucose, 2% FBS, 1X Glutamax, 1:200 ITS-X, 
10ug/ml Heparin, 10uM Zinc sulfate, 0.5µM SANT-1, 0.05µM Retinoic Acid, 200nM LDN-
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193189, 1µM T3 and 10µM ALK5i II. From day 14-28 cells were fed every day after with 
media that contains MCDB131 with 20mM glucose, 2% FBS, 1X Glutamax, 1:200 ITS-X, 
10ug/ml Heparin, 10uM Zinc sulfate, 200nM LDN-193189, 1µM T3, 10µM ALK5i II and 
100nM GSIS XX. From day 29-40 cells were fed every day after with media that contains 
MCDB131 with 20mM glucose, 2% FBS, 1X Glutamax, 1:200 ITS-X, 10µg/ml Heparin, 
10uM Zinc sulfate, 1µM T3, 10µM ALK5i II, 1mM N-acetyl cysteine, 10µM Trolox and 
2µM R428. 
 
Generation of genetic modified hESCs mediated by CRISPR-CAS9 
We used CRISPR-CAS9 nuclease system to generate all the different mutations use in 
this study. The CRISPR-CAS9 system used here consist in two plasmids, one carrying 
the CAS9 fused to a GFP (CAS9-GFP) addgene plasmid 44720, and the second 
plasmid was gRNA empty vector addgene plasmid 41824. The second plasmid was 
used to clone different gRNAs according to the gene of interest. 19bp of each gRNA 
were clone into the empty vector using In-Fusion HD (Clontech Cat No. 639647). The 
gRNAs used for each DNA region of interest were HNF1A: AACTGAGCCAGCTGCAGA, 
LINC01139 gRNA1: TGCGTACCAAAGATGTCGC and 
gRNA2:vCCGTATGTAATGATGTCTG.  
 
We perform lipid transfection of DNA plasmids with 30-50% confluent hESCs. Lipid 
transfection master mix was perform performed by incubating 50µl IMDM, 1ug of DNA of 
each plasmid and 4µl of DNA In-Stem (MTI Global Stem) incubate for 30min at room 
temperature. Then the 50µl reaction was added by drops to one well of 6-well plate. 24 
hours after transfection, GFP+ cells were sorted and replated on 1/3 matrigel with 
MEFS. After 10 days single colonies were picked and screening for indels. 
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Rapid DNA isolation and PCR: 
Each colony of hESCs that was picked for indel screening were resuspended in 20µl of 
PCR buffer containing of 50ug/ml proteinase K. Then samples were put at 55°C for 1h, 
94°C for 10 min. Samples were spin down and 5µl of the supernatant was used for PCR. 
For PCR reaction Platinum blue PCR supermix was used using 2mM of each primer, the 
PCR program used for PCR screen was: 90°C for 30 seconds, 98°C for 10 seconds, 
55°C for 20 seconds and 72°C for 30 seconds (go back to step 2 for 30x) finally, 72°C 
for 5 mins.  
 
Western Blot 
Protein from cell pellet was quantified using Pierce™ BCA Protein Assay Kit (Thermo 
Fischer scientific, cat No. 23227) 20ug of protein was load in 4-12% Bis-Tris SDS-
polyacrylamide gel (Invitrogen). Samples were transfer into a PVDF membrane (Thermo 
Fisher) and membrane blocking was performed using 2% nonfat dry milk. Primary 
antibody incubation was overnight and secondary antibody for one hour. Membrane was 
wash between antibodies incubation using 1X PBS-T three times each 10min. HRP was 
detected using Pierce™ TMB Substrate Kit and membrane was exposed to HyBlot CL 
autoradiography film (Denville Scientific) to visualized the protein band. 
 
Flow cytometry and cell sorting. 
Samples were broken until single cells and then fixed using 1.6% PFA incubating at 
37°C for 30min. Then for primary antibody, cells were wash twice using 1X saponin and 
primary antibody was incubated for 30min. For the secondary antibody samples were 
wash again using 1X saponin twice and incubate for 30min using the appropriated 
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secondary antibody. After 30min samples were washed twice using FACS buffer and 
then samples were resuspended in FACS buffer to be analyze by flow cytometry. 
 
Cell sorting cells was performed in two different way, for live cell sorting, cells were kept 
in their respective culture medium containing ROCK inhibitor (Cayman chemicals) and 
then replate according to how the cell grow, eg: CRISPR-CAS9 cell sorting plate in 
matrigel 1/3, for pancreatic derived insulin+ cells matrigel 1/30 was used. Cell sorting 
fixed cells for RNA isolation was performed according to describe for Hrvatin S et al 
2014. 
 
RNA isolation and cDNA synthesis 
For non fixed cells, PureLink RNA Micro Kit (Invitrogen Cat No 12183-016) was used 
and indication from manufacturer recommendations were followed. 16µl of free RNAse 
water was used to resuspend isolated RNA.  
 
For fixed cell, RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE was used (Ambion 
Cat No. AM1975) and manufacturer recommendations were followed (Hrvatin et al. 
2014). 30µl free RNAse water was used to resuspend isolated RNA.  
 
3µl of isolated total RNA was used for cDNA synthesis and SuperScript reverse 
transcriptase (Invitrogen Cat No 18064-022) was used as indicated in the manual. 
 
Microarray 
Three biological replicates of RNA from end stage pancreatic differentiation GFP+ 
NKX6.1+ fixed sorted cells were used to perform a genome profiling using a whole 
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human transcriptome with Affymetrix chip array performed by the Penn Molecular 
Profiling Facility. The data analysis was performed using XLSTAT software. All the 
genes and individual genotypes were clustered independently using ascendant 
hierarchical clustering based in Euclidean distances.  
Lentivirus production. 
293T cells were grow using 145mm plates using DMEM high glucose (4.5g/L) with 1X 
glutamine and 5% FBS. Cell were feed twice a week and were used to be infected with 
lentivirus when cells were 90% confluent. Lentivirus backbone used here was a second 
generation. Gene of interest is driven by Tet response element (TRE) and internal 
ribosome entry site (IRES) drives the expression of the red fluorescence protein (RFP) 
to facilitate to track down infected cells.  293T cells were transfected using 2 M CaCl2 
and HEPES with along with the helper plasmids: G protein of 
the vesicular stomatitis virus (VSV), Hgpm2, Tat and Rev. Virus was collected for 2  
days after transfection and lentivirus was use in pancreatic differentiation transducing 
50µl of lentivirus soup with  2 µg/mL polybrene (Millipore) and 2ml of medium in one well 
of 6-well plate. 
 
Glucose stimulation insulin secretion (GSIS) 
In order to check insulin secretion, we use Mel1-INS-GFP+ cells differentiated at day 30 
and cell sort for GFP+. 140000 cells were plate per well in a 96-well InVERT mold plate 
using day 31 media with 1uM of ROCK inhibitor. After 24 hours cells aggregated and 
media was replace without ROCK inhibitor and cells were fed every day after until day 
35 when the aggregated cells were used for the assay. The GSIS assay was performed 
in the InVERT mold with a total volume of 150µl. 
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We prepare KRBH ringer buffer by using three different solutions, solution A: NaCl 107g, 
solution B: KCl 5.96 g, NaHCO3 32.256g, MgCl2.6H2O 3.25g and solution Buffer C: 
CaCl2.2H2O 5.168g. For one litter we mixed 50ml of each solution and added 2g BSA + 
1.906g HEPES and brig it up to 1L using ddH2O, pH was adjusted 7.4. Buffer was filter 
and keep at 37C. Cells were incubated with KRBH buffer for 1h (starvation) then cells 
were incubated 2mM D-glucose for 30min (basal glucose) and 20mM D-glucose for 
30min and finally 30mM KCL for 30min. Supernatants were collected and keep at -80C 
until being use for C-peptide or insulin detection.  
  
EndoC-βH1 cell line. 
Cell line grow using DMEM low glucose as a backbone, then we prepare use a recipe for 
500ml as follow: 10g Bovine serum albumin (BSA) fraction V.  (Sigma A1470-100g), 
1.75µl beta-mercaptoethanol (BME) (Gibco Cat No. 21985023), 0.611g Nicotinamide 
(Sigma Cat N0636-100g), 55µl (50mg/ml) transferrin (Roche cat: 652202), 3.35µl 
(1mg/ml), Sodium Selenite and 5ml Pen/Strep (Gibco). Cell were split once they reach 
90% confluency and replate on plates coat 24 hours before using DMEM low glucose 
with 1/100 matrigel and 10yg/ml fibronectin. Cell splitting was performed using 0.25% 
trypsin and stop using BSA. Cells were split in ½ ratio. 
 
Mitochondrial Respiration and glycolysis stress. 
End of pancreas differentiation day 35, cell were sorted for GFP+ cells. 60000 cells were 
plated per well in a 96 well plate using 80µl of growth media. Next day before assay cells 
were wash using 200µl of sea horse media and then we added 175µl of respective 
medium for glycolysis of mitochondrial test. The respective concentrations of the 
different drugs used for the assay were for mitochondrial test 
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1.25µM oligomycin, 0.75µM FCCP, and 0.5µM Rotenone/Actinomycin. 
For glycolysis test we used 20mM D-glucose, 1.25µM oligomycin and 50mM 2-DG. 
Sample plate was transfer to a Seahorse XFe96 analyzer and results were analyzed 
using the free software wave. 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 6 software. The results are 
expressed as the mean ± standard error of the mean. An unpaired two-tailed Student’s t-
test for groups with equal variance were performed to determine p values. In figures 
*P<0.05, **P<0.01 and ***P<0.001. 
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List of primers for qRT-PCR 
 Table 2.1. List of primers used for qRT-PCR 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene$ FORWARD REVERSE
PDX1 GGAGCTGGCTGTCATGTTG CACTTCATGCGGCGGTTT
HNF1A GAGGACCCGTGGCGTGTGG GCCACCTCTCGCTGCTTG
NKX6.1 AAGAAGCACGCTGCCGAGATG CCGAGTTGGGATCCAGAGGCTTATT
INS TTTGTGAACCAACACCTGTGCGG GCGGGTCTTGGGTGTGTAGAAGAA
GCG TTCCCAGAAGAGGTCGCCATTGTT CAACCAGTTTATAAAGTCCCTGGCGG
SST GAGAATGATGCCCTGGAACCTGAAGA ATTCTTGCAGCCAGCTTTGCGT
PPY CCGCTGGACTTATAATGCCACCTTTC TTTATTGAGCCTGTCTGGGAGCAG
GHRL AGAAAGGAGTCGAAGAAGCCACCA CCCTTCTGCTTGACCTCCATCTTC
ARX CTGCTGAAACGCAAACAGAG TGAAGACGTCCGGGTAGT
IRX2 GCAGAGTTGTACCGCAGGAGAC GCCCTTCTACGGCAACTACACAAA
LRIG3 AAACCCCAGATCACGGTTC AGTCATTGGGGAATCACTGC
NPNT TACACCAAAGCCAACACCAA GTTGTCAGTCCGGTGGTTG
MUC13 TGCAGCTGATACCACTGAAACT GGGAGCAGGTGAAGTAGCTG
LOXL4 GTGATGAACGCCCAGCTAGT GAGAGGCAGTTCTCCTCGTG
CRYBA2 CCAGGGACAGCAGTTCATTC AGCAGCTGGTTGCTGTTGT
LDB2 CATCCCCCGTTACTTTAGCA CGTGATGGATGAGTTGTGGT
RGS4 CGGTCGTAGCTGGGCTATAA TTCGGCTTTGAGCGTACTTT
PPP1R1A AACATCACCTGGGGCAAC CAGCCTTGACTCCACTTCTG
DPP4 TATGCAGGCCCATGTAGTCA ACTTCCTCTGCCATCAAAGC
GC CAGCACTGTCTGCCAAGT TTCAGAGCAGCCATGCAGA
ITGA1 GGAGCCTATGATTGGAATGG GAAGCAAGCGGTTCATTCTT
KIF12 CAAACCTGGCCCAGAGACT CTCACTGCAGGGTGGCT 
PAX4 TTACTACCGCACAGGTGTCTTGGA CAGCACAAAGCTGGCGTTGGATTT
RFX6 TCCATCACACTGCTCCACAT GGCTGTGCCCTAAACACAGT
GLIS3 AGCCTTGCTAACAACCTCCA CATTTGTCTCCTGGGGCTTA
HNF4A TCCAACCCAACCTCATCCTCCTCCT TCCTCTCCACTCCAAGTTCCTGTT
MT1F GCTGCTGCTCCTGCT GCAGCAGCTGCACTTCTC
MT1H TGCTGCTCCTGTTGCC AGCAGCTGCACTTCTCTG
PCSK1 TCCGTGGATCCAGAGGTGGTTATG TGTGGCTGAGAAAGGAGACAGGTATA
ERO1LB CAAACACCGCTTTGACCCTG GCCACCTTTGACAAAGCTCG
G6CP2 CGACATGCCACAAAGGCACAGTAT ATGAGCACTCCATTCCTGTGAAGG
ADH6 GGGTTGTAAAGCAGCAGGAG GGTTGAGGCACTCAGTAGCA
ALDH1A1 TGTTGTATAGCCGCATCCAG CTCCTGGGGTCAGAGGATTT
PKM GAAGGGTGTGAACCTTCCTG GATGAATGACGCAAACACCA
LDHA CTGCAAACTCCAAGCTGGTC CACGTTACGCTGGACCAA
ACLY CATCTATGCCACCCGAGAAG AGTTTCTCATCCACGCCAAC
IDH1 GCGTCAAATGTGCCACTATC TGCCACCCAGAATATTTCGT
COX11 GCCGAGAGAGGACTGAGGT AAGGGTTCGAGCTCTTAGGC
ATP2A3 TCATCACTACATGCCTGGCA TTGTCGGAGCAGATGACTGA
ATP2B1 GGAGCTGCAATCCTCTTGTC CTTGTTCAATTCGGCTCTGC
ATP5O TCCTGAAGGAACCCAAAGTG TGGTAGTGAGGGGAGAGAACC
UCP2 GCAGGCAGCACCACAGGT GACGGTGCTTTGGTATCTC
LINC01139 GGCTACATAACCTGCCAAC ATGAAAACATATTCAACCTCAGT
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List of antibodies 
Table 2.2. List of antibodies used for protein quantification (Flow cytometry, Immunoblot) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIBODY COMPANY CATALOG
HNF1A Cell)Signaling D7Z2Q
HNF1A Santa)Cruz SC86547
PDX1 R&D BAF2419
NKX6.1 BSHB F55A10
INSULIN Sigma I2018
C8PEPTIDE Cell)Signaling 4593S
SOMATOSTATIN Santa)Cruz YC7
GLUCAGON Sigma G2654
β8Actin Sigma A1978
Rat)IgG2a)Isotype Thermo)Fischer (0289688)
Rabbit)IgG)Isotype Cell)Signallin 3900S
Mouse)IgG1)isotype Cell)Signaling) 5415s
Primary3Antibodies
ANTIBODY COMPANY CATALOG
Goat%anti%Rabbit*IgG%*Alexa488 Jackson*Immunoresearch* 111-546-144
Goat%anti%Rabbit*IgG%*Phycoerythrin* Jackson*Immunoresearch* 111%116%144
Donkey*Anti%Rabbit*IgG%647 Jackson*Immunoresearch* 711-606-152
Goat%anti%mouse*IgG1%*Phycoerythrin Jackson*Immunoresearch* 115%545%205
Goat%anti%mouse*IgG1%*Alexa647 Jackson*Immunoresearch* 115%115%205
Goat%anti%mouse*IgG1%*Alexa488 Jackson*Immunoresearch* 115%605%205
Streptavidin%*Pacific*Blue* Invitrogen* S11222
Streptavidin%*Alexa647 Invitrogen* S32357
Goat%anti%mouse*IgG%HRP Biorad 1721011
Donkey%anti%goat%IgG%HRP Santa*Cruz sc%2020
Secondary7Antibodies
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RESULTS 
 
HNF1A expression during the generation of beta-like cells in vitro. 
In order to interrogate the role of HNF1A in the human ESC system, we used two 
different genetic backgrounds, Mel1 INS-GFP where GFP is expressed from the INS 
locus (Micallef et al. 2012) and H1 (Thomson 1998). This approach allowed us to focus 
on HNF1A intrinsic phenotypes and disregard genetic background specific phenotypes. 
We differentiated human ESCs to beta-like cells following the protocol developed by 
Rezania et al. 2014, with some minor modifications. We examined four stages during 
pancreas differentiation: definitive endoderm (DE) characterized by the co-expression of 
CXCR4 and CD117 at day 3, pancreatic progenitor one (PP1) with the presence of 
PDX1+ cells from days 7-12, pancreatic progenitor two (PP2) at days 12-15 with cells 
co-expressing PDX1 and NKX6.1 and finally beta-like cells from days 15-40 when cells 
express the pancreatic hormone insulin (Figure 2.1A). We examined HNF1A at the 
mRNA and protein level during the four stages of pancreatic differentiation to establish 
the kinetics of HNF1A expression during differentiation. HNF1A transcript levels reached 
its maximum peak at PP2 along with similar kinetics to the transcription factor NKX6.1 
and maintained its expression until the end of the pancreatic differentiation (Figure 
2.1B). These data were confirmed at the protein level using intracellular flow cytometry 
(Figure 2.1C). Next, we checked if the transcript levels of HNF1A from ESC derived beta 
cells were comparable to beta cells in primary human islets. We sorted cells based upon 
expression of the pancreatic hormones: somatostatin (SST), Glucagon (GCG) and 
Insulin (INS) from adult human islet donors. These populations were compared sorted 
ESC derived beta like cells (INS-GFP+ NKX6.1+). We found that in vitro derived beta 
cells express comparable HNF1A transcript levels and also that HNF1A is also 
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expressed in all the three-pancreatic hormone populations in the human islet (Figure 
2.1D).  
  
Deficiency of HNF1A influences pancreatic hormone expression. 
To dissect the function of HNF1A during pancreas differentiation, we generated 
heterozygous (HET) and homozygous (KO) HNF1A null mutants in the human ESC lines  
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Figure 2.1: HNF1A expression during the generation of beta-like cells in vitro. 
(A) Schematic representation of the protocol used to derive beta-like cells from ESCs.  
(B) Relative mRNA expression quantified by qRT-PCR. Time-course quantification to 
determine the kinetics expression of HNF1A during pancreas differentiation using genes 
that determine specific stages of the pancreatic differentiation eg: PDX1 for pancreatic 
progenitor one (PP1), NKX6.1 pancreatic progenitor two (PP2), INSULIN derived beta-
like cells (n=3 per sample)  
(C) Flow cytometry (FMC) showing HNF1A protein histograms during pancreas 
differentiation. Definitive endoderm (DE), PP1, PP2 and beta-like cells (n=3 per cell line)   
(D) Relative HNF1A mRNA expression in derived beta-like cells and human islets sorted 
for pancreatic hormones Insulin (INS), somatostatin (SST) and glucagon (GCG) (n=3 per 
sample) 
 
Mel1-INS-GFP and H1. The CRISPR-CAS9 nuclease system was used to target HNF1A 
at exon one, utilizing DNA oligo templates to introduce a premature stop codon or 
control silent mutations to prevent indel formation and allow the generation of both 
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heterozygous and homozygous mutations (Figure 2.2A). The wild-type (WT) HET and 
KO ESC lines were differentiated to the PP2 stage and a western blot was performed to 
quantify HNF1A protein levels. The HET cell line showed a reduced amount of HNF1A 
protein and in the KO cell line HNF1A protein was completely absent. A similar result 
was found when protein was assayed by intracellular flow cytometry (Figure 2.2B and 
2.2C). We proceeded to examine if HNF1A impacted pancreatic differentiation during 
three differentiation stages (Figure 2.1A). First, we quantified PDX1 at the PP1 stage 
and found that there were no significant differences between any of the genotypes 
(Figure 2.2D,I). Second, we examined the percentage of PDX1+NKX6.1+ cells generated 
at the PP2 stage and found similar efficiencies in all the genotypes as well (Figure 
2.2E,J). Finally, at the end of the pancreatic differentiation, cells were stained for C-
peptide (C-PEP), glucagon (GCG) or somatostatin (SST). The C-PEP+ population 
ranged between 35-55% in the Mel1 ESC line (Figure 2.2F,K) and 45-75% in the and H1 
ESC line, but with no differences seen in the percentage of cells positive for C-PEP in 
mutant lines in these two genetic backgrounds. The GCG population in the Mel1 
background was increased in the HET and KO lines, roughly double found in the WT 
(Figure 2.2G,L). Similar results were found in the H1 genetic background. Finally, while 
the SST population was unchanged in the Mel1 genetic background (Figure 2.2H,M), in 
the H1 genetic background the HET cell line generated an increase in SST+ cells when 
compared to the WT cell line.  
 
It was somewhat surprising that the HNF1A KO ESCs generated a similar percentage of 
C-PEP+ cells considering that mouse models can present with a reduction in beta cell 
mass and a decrease in insulin expression. We therefore examined the amount of 
insulin present in cells expressing INS in the human ESC differentiation cultures. Using 
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the reporter Mel1 INS-GFP cell line we found that the KO line had lower GFP 
fluorescence intensity (Figure 2.2N).  
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Figure 2.2: Deficiency of HNF1A influences pancreatic hormone expression. 
(A) CRISPR-CAS9 strategy to generate HNF1A heterozygous and Knock-out hESCs. 
(B-C) Representative intracellular flow cytometric analysis of HNF1A performed at PP2 
stage using HNF1A allelic series. Experiments were repeated at least three times per 
cell line. (B) Histogram representation of HNF1A (C) HNF1A mean fluorescence 
intensity  
(D-M) Flow cytometry quantification of specific proteins during pancreatic differentiation 
using HNF1A allelic series. D,I. Percentage quantification of PDX1+ cells at PP1 (n=4 
per genotype) (E,J) Percentage quantification of PDX1+ NKX6.1+ (PP2) (n=4 per 
genotype). (F,K) Percentage quantification of C-peptide+ cells end of differentiation 
protocol beta-like cells (n=6 per genotype) (G) Percentage quantification of glucagon+ 
cells at end of differentiation (n=6 per genotype)  (H) Percentage quantification of 
somatostatin+ cells at end of differentiation (n=6 per genotype)   
(N) Aggregates at end stage of differentiation using the Mel1 INS-GFP cell line showing 
GFP fluorescence intensity in HNF1A allelic series. Bar graph size 300µM  
(O) Quantification of C-Peptide Mean Fluorescence Intensity (MFI) at the end of 
differentiation protocol beta-like cells (n=3 per sample)  
(P) qRT-PCR quantification for pancreatic hormones Insulin (INS), glucagon (GCG), 
somatostatin (SST) and ghrelin (GHRL) at the end of pancreatic differentiation in bulk 
cells (n=3 per sample) 
 
 
The impact on insulin was corroborated by quantification of C-Peptide by flow cytometry 
in the KO cell line compared to the WT or HET (Figure 2.2O). This finding was also 
observed in the H1 genetic background. INS mRNA levels were also decreased in the 
KO cell line but not in the HET line compared to the WT line. We were interested in 
quantifying the transcript levels of other pancreatic hormones and found that SST and 
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PPY did not have any difference between genotypes but GCG and GHRL were both up-
regulated in the HET and KO lines (Figure 2.2P) in both genetic backgrounds. These 
data suggest that HNF1A is an important regulator of endocrine hormone gene 
expression, either directly or via impacts on differentiation. 
 
Ablation of HNF1A drives pancreatic endocrine differentiation toward cells with a 
more alpha cell gene expression signature. 
In vitro differentiation can yield monohormonal endocrine populations as well as 
polyhormonal cells, which co-express multiple hormones. In order to examine these 
subpopulations, we performed flow cytometry analysis, co-staining for GCG, C-PEP and 
SST. We focused our analysis on GCG and C-PEP as SST did not co-stain with GCG+ 
cells and only a very small percentage of SST co-stained with C-PEP+ cells (Data not 
shown).  We analyzed C-PEP versus GCG staining and quantified polyhormonal cells 
(GCC+C-PEP+) and monohormonal GCG+ or C-PEP+ populations (Figure 2.3A). We 
found that the loss of one or two alleles of HNF1A leads to an increase in GCG either 
driving more double positive GCG+CPEP+ in the HET or monohormonal GCG+ cells in 
the KO while the monohormonal C-PEP+ cell population was significantly reduced 
(Figure 2.3B-C) .In mouse models, the transcription factors PAX4 and ARX have  well 
described roles in driving beta and alpha cell fates respectively (Collombat et al. 2003; 
Courtney et al. 2013).  We hypothesized that HNF1A may play a role in upregulating 
ARX and/or downregulating PAX4 during pancreatic differentiation leading to the 
observed differences in hormone expression in the mutant lines.  We examined mRNA 
expression of PAX4 and ARX in a time-course analysis at four different stages of the 
differentiation. We found that PAX4 and ARX are expressed during PP2 but PAX4 is 
downregulated in the HNF1A HET line and even more so in the KO line in both Mel1 and 
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H1 ESCs (Figure 2.3E).  When we looked at the ARX transcript levels, we saw 
upregulation in KO cells line at the beta-like cell stage (Figure 2.3F).  Due to the 
increased GCG+ cells in the HNF1A mutants, we wanted to determine if this difference 
would encompass a wider gamut of alpha cell specific genes. We quantified mRNA 
levels of a set of alpha cell specific genes reported previously (Muraro et al. 2016), in 
addition to GCG and ARX, which we had already examined.  We found five of these 
genes are significantly upregulated in the HNF1A KO (NTPN, LOXL4, CRYBA2, LDB2, 
and RGS4) (Figure 2.3G).  Overall, these data suggest that HNF1A deficiency impacts 
endocrine cell development via PAX4 and ARX and leads to de-repression of alpha cell 
genes. 
 
HNF1A is needed for optimal insulin secretion and cellular respiration in stem cell 
derived beta-like cells. 
Humans with heterozygous mutations of HNF1A display hyperglycemia, so we sought to 
determine the functionality of the beta-like cells lacking HNF1A. In order to perform 
glucose stimulated insulin secretion (GSIS) we used the Mel1 INS-GFP+ cell line to sort 
INS-GFP+ cells from each genotype at the end of pancreatic differentiation.  We plated 
purified cells in an InVERT micro-wells to generate clusters of uniform size (Stevens et 
al. 2013). The INS-GFP+ cell aggregates were exposed to low and high glucose levels, 
2mM and 20mM respectively and insulin secretion was quantified in the media.  
We found that the HET and KO cell lines failed to respond to high glucose with a 
stimulation index near 1 while the WT cell line had a stimulation index of 2-3 (Figure 
2.4A) The failure of stimulation index may have several causes such as normal basal 
secretion and poor response to high glucose or higher basal secretion.  We found that 
the mutant lines both had a trend towards an increased basal secretion as well as a 
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significant decrease in secretion at higher levels of glucose in the KO and these defects 
together led to the failure in stimulation index (Figure 2.4B and C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Ablation of HNF1A drives pancreatic endocrine differentiation toward 
cells with a more alpha cell gene expression signature. 
(A) Flow cytometry of C-Peptide and GLUCAGON at the end stage of pancreas 
differentiation in HNF1A allelic series (n=6 per sample) 
(B-D) Quantification of pancreatic hormones (n=6 per sample) (B) C-Peptide+ (C-PEP+) 
monohormonal cells (C) GLUCAGON+ (GCG+) monohormonal cells (D) C-Peptide+ 
GLUCAGON+ (C-PEP+GCG+) cell population 
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(E-F) mRNA time-course analysis during pancreatic differentiation DE, PP1, PP2 and 
beta-like cells (n=3 per sample) (E) PAX4 mRNA expression (F) ARX mRNA expression 
(G) Relative gene expression of alpha specific cell genes at end stage of differentiation 
in HNF1A allelic series (n=3 per sample) 
For all statistical analysis: * P<0.05, **P<0.01, ***P<0.001 
 
To determine why the HNF1A mutants present with abnormal insulin secretion, we 
analyzed upstream pathways critical for GSIS including glycolysis and mitochondrial 
respiration using extracellular flux analyzer (Seahorse Bioscience). WT and mutant beta-
like cells from the Mel1 line were purified by INS-GFP expression. To measure 
glycolysis, we calculated the extracellular acidification rate (ECAR) in the presence of 
glucose, oligomycin and 2-DG (Figure 2.4). The ECAR was significantly lower in HET 
and KO compared to WT cell line (Figure 2.4E). Maximum glycolysis capacity was also 
lower in HET and KO compared to WT (Figure 2.4F). Next, we proceed to determine if 
HNF1A plays a role in mitochondrial respiration. For each genotype of the HNF1A we 
measured the maximal respiration capacity of the cells by measuring oxygen 
consumption rate (OCR) upon stimulation in response to oligomycyn, FCCP and 
rototenone/actinomicin (Figure 2.4G). We observed that the HET line presented a lower 
oxygen consumption than the WT or KO cell lines (Figure 2.4H). These studies were 
repeated with the H1 ESC line with bulk cultures which where ~50% INS+ cells (Figure 
S5) with similar results.  These data suggest that HNF1A is critical for glucose 
metabolism as well as mitochondrial function.  In addition, the mitochondrial phenotype 
was only present in the HET in both genetic backgrounds, suggesting a complex 
regulation of mitochondrial function. 
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Figure 2.4: HNF1A is needed for optimal insulin secretion and cellular respiration 
in stem cell derived beta-like cells. 
(A-C) Glucose stimulation insulin secretion (GSIS) in HNF1A allelic series using purified 
INSULIN-GFP+ cells at end stage of differentiation (n=3 per sample) (A) Stimulation 
index of insulin secreted showing fold change 20mM over 2mM glucose. (B) 
Quantification of insulin secreted per insulin positive cell using 2mM glucose (C) 
Quantification of insulin secreted per insulin positive cell using 20mM glucose 
(D-F) Glycolysis stress test for HNF1A allelic series (n=3 per sample) (D) Glycolytic 
profile of HNF1A allelic series showing as a extracellular acidification rate (ECAR) 
normalized at basal levels (E) Glycolysis quantification (F) Glycolisys capacity  
(G-H) Mitochondria stress test (n=3 per sample) (G) Mitochondrial respiration profile of 
HNF1A allelic series obtained using oligomicin, FCCP and Rototenon/actinomicin 
(Rot/Act) (H) Quantification of maximal respiration capacity. 
For all statistical analysis: * P<0.05, **P<0.01, ***P<0.001 
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Disruption of HNF1A leads to an abnormal expression of genes related with beta 
cell function, development and diabetes. 
To understand the mechanism by which HNF1A loss leads to the functional phenotypes 
in beta-like cells described above, we performed genome wide gene expression analysis 
on end stage pancreatic differentiation cells from the Mel1 ESC line. To limit our studies 
to the most relevant cell type, the INS-GFP+NKX6.1+ population from each genotype 
was cell sorted and used for microarray analysis (Figure 2.5A). 501 genes were found to 
be differentially expressed where 60% of these genes are downregulated and 40% are 
upregulated in the KO cell line series (Figure 2.5B). Using this dataset of 501 genes we 
examined the top most downregulated and upregulated genes (Figure 5C). Many of the 
top downregulated genes were also reported downregulated in the HNF1A mouse model 
such as PPP1R1A, DPP4, GC, KIF12 and ITGA1 (Figure 2.5C). The downregulated 
genes in the mouse were found also be downregulated in human HNF1A HET and KO 
beta-like cells by QRT-PCR in both the Mel1 and H1 genetic backgrounds (Figure 2.5D). 
We also validated 5 critical beta cell transcription factors from the microarray by QRT-
PCR (Figure 2.5E).  These five genes are monogenic diabetes or MODYs and only 
HNF4A and PDX1 had been reported in mouse models (Horikawa 2018; Hattersley & 
Patel 2017). To confirm these results in another experimental system, we used CRISPR-
CAS9 to generate indel mutations in HNF1A in the human beta cell line EndoC-BH1 
(Figure S8A-D) (Ravassard et al. 2011). We generated EndoC-BH1 cells with a loss of 
HNF1A protein in ~90% of the population and gene expression analysis confirmed both 
the mouse target genes as well as the beta cell transcription factor targets (Figure S8E-
F). 6 of the top 7 downregulated genes are members of the metallothionein gene family 
(Figure 2.5C). Metallothionein gene family are intracellular metal binding proteins that 
work as a potent antioxidant and adaptative stress and overexpression of these gene 
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family in pancreatic beta cells confer resistance to oxidative stress, apoptosis and 
prevent diabetes development (Cai 2004; Nygaard et al. 2015). We validated two of 
these genes by QRT-PCR (MT1F and MT1H) as well as two other genes involved in 
insulin biosynthesis that were PCSK1 and ERO1LB (Figure 2.5F). It was interesting to 
see that the top 10 upregulated genes are not related with pancreas and 8 out of 10 
genes are expressed in intestine according to the human protein atlas (Uhlen et al. 
2015).  These data propose that HNF1A is a regulator of genes involved in beta cell 
function, cell protection and insulin processing but also HNF1A present different gene 
regulation between human and mouse models.  
 
Considering the metabolic phenotypes seen in the HNF1A mutants cells (Figure 2.4), we 
looked for genes which were dysregulated in the HNF1A KO cells that are related to 
cellular respiration (glycolysis, Acetyl-CoA, and oxidative phosphorylation) (Figure 2.5G) 
At the glycolysis pathway using qRT-PCR we validated known genes in pancreatic beta 
cells like G6CP2 and LDHA but also new target genes related with glycolysis like ADH6 
and ALDH1A1. G6CP2 was downregulated and this gene is a regulator of glucose cycle 
with implications in insulin secretion (Li et al. 2009). Additionally, upregulation of LDHA 
decreases insulin secretion and deregulates mitochondrial metabolism (Ainscow et al. 
2000). We also looked downstream on the cell metabolic pathway and found genes 
deregulated in Acetyl-CoA like ACLY and IDH1, which are important genes in lipid 
metabolism and production of NADPH (Calvert et al. 2017; Beckner et al. 2010). Finally, 
looking at genes related with oxidative phosphorylation we found COX11 and ATP2A3 
mRNA being downregulated and UCP2 upregulated, these genes have being described 
as mitochondrial metabolism regulators and T2DM human islet gene profile present  
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Figure 2.5: Disruption of HNF1A leads to an abnormal expression of genes related 
with beta cell function, development and diabetes. 
(A-B) HNF1A allelic series genome profiling using purified INS-GFP+ NKX6.1+ cells at 
the end of differentiation protocol (n=3 per sample)  (A) Flow cytometry plot for sorting 
double positive INS-GFP+ NKX6.1 cells (B) 501 differential expressed genes 
represented in a heat map plot obtained using a microarray analysis. 
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(C) Differential expressed genes display in top downregulated genes, top downregulated 
genes, cellular respiration and genes and genes differential expressed in HET compared 
to KO 
(D-G) qRT-PCR gene expression validation (n=3 per sample)  (D) Mouse HNF1A target 
genes (E) Pancreas transcription factors (F) cell stress and insulin biosynthesis (G) Cell 
respiration 
For all statistical analysis: * P<0.05, **P<0.01, ***P<0.001 
 
similar patterns of differential gene expression to HNF1A mutants (Taneera et al. 2014; 
Olsson et al. 2011; Zhang et al. 2001).  The data provide here, suggest that HNF1A may 
be involve in regulation of glycolysis and mitochondrial function by regulating genes 
related with cellular respiration in derived beta-like cells.  
 
The human specific lncRNA, LINC01139 (LINKA), is a downstream target of 
HNF1A. 
In Figure 2.4G we noticed a very interesting mitochondrial phenotype that was present 
only in the HET mutants but not in the KO. To find gene targets for this phenotype, we 
utilized our genomic dataset to look for genes that were deregulated to a larger degree 
in the HNF1A HET compared to the KO. In Figure 2.5C, right column (HET/KO), we list 
the HNF1A gene targets where the fold change difference from WT was larger in the 
HET as compared to KO.  The top downregulated target that we observed was a 
lncRNA, LINC01139 named LINKA which was downregulated over 3-fold more in the 
HET as compared to the KO HNF1A beta-like cells (Figure 2.5C and 2.6A). We 
examined LINKA expression during pancreas differentiation and we found that its 
expression increases at the PP2 stage and reaches its peak of expression at the beta-
like cell stage (Figure 2.6B). LINKA is located in the human genome in the chromosome 
one, it is present in primates without homology in mouse or rat genomes (Figure 2.6C). 
To corroborate that LINKA is expressed not only in our in-vitro system we examined its 
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expression in primary humans islets cell sorted into the three main endocrine hormone 
expressing cell types as well the EndoC-BH1 cell line.  While being expressed at the 
highest levels in beta-like cells, it was also expressed in three main pancreatic endocrine 
cell types as well as the beta cell line (Figure 2.6D). Furthermore, LINKA is expressed 
during fetal pancreas development in endocrine cells at week 18 (Figure S9A). To 
corroborate that HNF1A can regulate LINKA expression in a different experimental 
system, we quantified LINKA expression in EndoC-BH1 cells where HNF1A expression 
was diminished using either HNF1A-shRNA or CRISPR-CAS9 for HNF1A (Figure 2.6E). 
We find that in both methods to decrease HNF1A expression led to decreased LINKA 
expression (Figure 2.6F). We find that in both methods to decrease HNF1A expression 
led to decreased LINKA expression.  
 
While LINKA has not been studied in the context of the pancreas, in cancer cell lines it 
has been demonstrated to be a positive regulator of AKT signaling (Lin et al. 2017). 
Therefore, we decided to look for the role of LINKA in T1DM or T2DM but looking at 
gene expression profiles of LINKA under this two populations and surprisingly LINKA 
was highly upregulated in isolated beta cells from T1DM donors (Figure S9D), which 
could be due to the beta cells being under stress. It is known that AKT singling can play 
an important role in many biologic processes, including stress signaling and we 
hypothesized that LINKA may be involved in stress signaling in beta cells.  In order to 
test this hypothesis, we exposed the EndoC-BH1 human beta cell line to different 
stressors including high glucose (HG), IL-6 or both for 24 hours. We found that LINKA 
showed increased expression in response to either IL-6 or HG+IL6 (Figure 2.6F). 
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Figure 2.6: The human specific lncRNA, LINC01139 (LINKA), is a downstream 
target of HNF1A. 
(A-B) qRT-PCR LINC01139 mRNA quantification (n=3 per sample) (A) HNF1A allelic 
series purified INS-GFP+ end stage beta-like cells (B) Time-course LINC01139 mRNA 
quantification during pancreatic differentiation  
(C) LINC01139 gene homology, modified from UCSC genome browser comparing 
Human vs Rhesus, mouse and rat. 
(D) LINC01139 mRNA quantification comparing purified beta-like cells with hormones 
subpopulation of human islets (n=3 per sample) 
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(E-F) Protein and mRNA HNF1A quantification in EndoC-βH1 cell line with/out HNF1A 
shRNA (n=3 per sample) (E) HNF1A histogram representation (F) HNF1A relative 
mRNA levels. 
(G) LINC01139 mRNA quantification in EndoC-βH1 cell line treated with different beta 
cell stressors: high glucose (100mM) (HG), Interleukin 6 (IL-6) (50ng/ul) or both (n=4 per 
sample)    
(H) qRT-PCR quantification for LINC01139 mRNA in wild-type line (WT) and deleted 
LINC01139 cell line (DEL)  
(I-M) Pancreatic differentiation of LINC wild-type (WT) and deleted LINC01139 cell line 
(DEL) with quantification of specific proteins by flow cytometry. (I) Percentage 
quantification of PDX1+ cells at PP1 (n=4 per sample)  (J) Percentage quantification of 
PDX1+ NKX6.1+ (PP2) (n=4 per sample) (K) Percentage quantification of C-peptide+ 
cells end of differentiation protocol beta-like cells (n=6 per sample)   (L) Percentage 
quantification of glucagon+ cells at end of differentiation (n=6 per sample) (M) 
Percentage quantification of somatostatin+ cells at end of differentiation (n=6 per 
sample)    
(N) qRT-PCR quantification for pancreatic hormones Insulin (INS), glucagon (GCG), 
somatostatin (SST) and ghrelin (GHRL) at the end of pancreatic differentiation in bulk 
cells (n=3 per sample)    
(O) Quantification of C-Peptide Mean Fluorescence Intensity (MFI) at the end of 
differentiation protocol beta-like cells (n=3 per sample)    
For all statistical analysis: * P<0.05, **P<0.01, ***P<0.001 
 
 
In overall, this data shows that LINKA is a downstream target of HNF1A and LINKA 
could potentially play a role in response to cell stress in pancreatic beta cells. 
 
We decided to interrogate the role of LINKA in pancreas differentiation and beta cell 
function, utilizing the CRISPR-CAS9 nuclease system to generate Mel1 and H1 ESCs 
deficient in LINKA (figure S9B-C) The LINKA deficiency was confirmed by QRT-PCR, 
using primers outside the region of the deletion, we find a loss of LINKA message at the 
B-cell stage of pancreas differentiation (Figure 2.6H). We then analyzed the impact of 
loss of LINKA on pancreatic differentiation.  During the differentiation LINKA deficient 
lines have similarly differentiation efficiency to the WT at the PP1 and PP2 stages 
(Figure 2.6H-J). Then we characterized the generation of endocrine cells and we didn’t 
see significant differences in generation of C-PEP+, SST+, or GCG+ cells in the Mel1 
background (Figure 2.6J-L) but we saw a slight increase in GCG+ and SST+ cells. We 
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also looked at the mRNA levels of the different hormones using bulk end stage cell 
differentiation cultures, where GCG showed a slight upregulation but only in the Mel1 
background (Figure 2.6M). C-peptide protein content was similar in both genetic 
backgrounds (Figure 2.6N). These data demonstrates that LINKA does not impair 
pancreatic differentiation but it slightly increases glucagon. 
 
Lack of LINKA mimics a subset of the phenotypes found in HNF1A mutant cells. 
While the LINKA deficient cells did not show with dramatic changes in endocrine cell 
development, we were interested in examining different glucagon+ subpopulations that 
presented with more severe phenotypes in the HNF1A mutant cell lines (Figure 3).  We 
saw a similar increase in GCG+ monohormonal cells in both genetic backgrounds of 
LINKA mutant cells (Figure 7A, 7C and S7A and S7C) while the decrease in 
monohormonal C-PEP+ cells was only seen in the H1 background (Figure 2.7B and 
S7B). Due to the similar phenotype than HNF1A mutants; we use a similar approach to 
quantify mRNA levels of genes that could influence GCG expression. We isolated RNA 
from bulk cells at end stage of pancreatic cell differentiation and we observed an 
increase in ARX expression and decrease in PAX4 (Figure 2.7E), but this result was not 
recapitulated in the H1 genetic background (Figure S7E). We also measured alpha cell 
specific genes and LOXL4 and CRYBA2 were upregulated in LINKA mutant lines in both 
genetic backgrounds (Figure 2.7F and S7F). Overall, these studies show a similar but 
less severe phenotype in alpha cell gene de-repression in the LINKA deletions mutants 
as seen in the HNF1A mutant stem cell lines. 
Next, we decided to explore cellular respiration in beta-like cells deficient of LINKA to 
see if LINKA could explain some of the phenotypes seen in HNF1A heterozygous lines. 
We quantified oxygen consumption using the mitochondrial stress test.  We saw lower 
	  56	  
maximal respiration in LINKA deficient cells, mimicking the phenotype seen in the 
HNF1A HET cells.  
 
Next we decided to compare downstream target genes of HNF1A that could be 
regulated via LINKA. We focused our analysis on sorted INS-GFP+NKX6.1+ cells, 
comparing LINKA deficient with the WT lines. We found that the lack of LINKA leads to a 
downregulation of subset of HNF1A mouse targets genes including DPP4, GC, and 
ITGA1.  Genes relating to cell stress (MT1F, MT1H), insulin biosynthesis (PCSK1, 
ERO1LB), and the pancreas transcription factor (PAX4) and glycolysis (ADH6) were also 
impacted (Figure 2.7L-M). But not all genes were recapitulated in H1 genetic backfround 
like PAX4 and ERO1LB. These results imply that LINKA function by regulating a subset 
of HNF1A target genes with implications in cellular respiration. 
 
DISCUSSION 
While MODY3, caused by heterozygous mutations in HNF1A, is the most common 
monogenic form of diabetes (Fajans & Bell 2011), how HNF1A contributes to disease 
pathogenesis in human beta cells remains unclear. This is in part due to the failure of 
mouse models to mimic the human phenotype and the difficulty to access patient 
samples. In this study, we developed a human stem cell model that allows the study of 
the molecular mechanisms by which HNF1A regulates both beta cell development and 
function.   
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Figure 2.7: Lack of LINKA mimics a subset of the phenotypes found in HNF1A 
mutant cells. 
A) Flow cytometry of C-Peptide and GLUCAGON at the end stage of pancreas 
differentiation in HNF1A allelic series 
(B-D) Quantification of pancreatic hormones (n=6 per WT and n=5 per LINC mutant cell 
line) (B) C-Peptide+ (C-PEP+) monohormonal cells (C) GLUCAGON+ (GCG+) 
monohormonal cells (D) C-Peptide+ GLUCAGON+ (C-PEP+GCG+) cell population 
(E) PAX4 and ARX mRNA expression at end of pancreatic differentiation in bulk cells 
(n=3 per sample)    
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(F) Relative gene expression of alpha specific cell genes at end stage of differentiation in 
deleted LINC01139 cell line (n=3 per sample)     
(G-H) Mitochondria stress test using oligomicin, FCCP and Rototenon/actinomicin 
(Rot/Act) in deleted LINC01139 cell line compared to WT cell line (n=3 per sample) (G) 
Mitochondrial respiration profile (H) Quantification of maximal respiration capacity 
comparing WT and LINC01139 deleted cell lines. (n=3 per genetype) 
(I-J) mRNA quantification of HNF1A downstream target genes between WT and deleted 
LINC01139 using purified INS-GFP+ NKX6.1+ at end stage differentiation samples (n=3 
per sample)   
 
 
The use of multiple isogenic lines has been critical, as we identify specific phenotypes of 
HNF1A mutants independent of genetic background.  These include de-repression of an 
alpha cell gene expression signature (Figure 2.3A), defective insulin secretion (Figure 
2.4A), cellular respiration (Figure 2.3D-H) and regulation of specific genes and a lncRNA 
(Figure 2.6A) not present in rodent models and which contributes to the HNF1A 
phenotype (Figure 2.7L-M). 
In this study, we found that even complete loss of HNF1A does not impair the generation 
of pancreatic progenitors but it is necessary for proper endocrine cell development.  
First, we show that the complete loss of HNF1A led to significant downregulation of 
insulin mRNA and protein content which is similar o observations reported in mouse 
models due to direct regulation of insulin transcription (Akpinar et al. 2005; Wang et al. 
2000; Brial et al. 2015). Second, HNF1A HET and KO cells up-regulate expression of 
the hormones ghrelin and glucagon with a decrease of insulin monohormonal cells 
(Figures 2.2). We hypothesize that this phenotype may be due to HNF1A regulation of 
PAX4 expression. Our results show that the lack of HNF1A reduces PAX4 mRNA levels 
throughout pancreatic differentiation resulting in ARX and ghrelin up-regulation. These 
findings, while not seen in HNF1A rodent models, are consistent with some of the 
phenotypes described in PAX4 null mouse models. Here, the main phenotype in the 
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pancreas was a dramatic increase in the ghrelin and glucagon cell populations with loss 
of most insulin+ cells (Collombat et al. 2003). Our human stem cell model while having 
the first two phenotypes still do generate beta-like cells, but the human HNF1A mutants 
still transiently express PAX4 at low levels during development (Figure 2.3E). This low 
level expression may be sufficient for beta cell generation, or alternatively, PAX4 could 
have distinct roles in mouse and humans in regard to beta cell development.  In the 
mouse, it was also shown that PAX4 is a repressor of ghrelin expression via the ghrelin 
promoter (Wang et al. 2008). Moreover, PAX4 is a repressor of ARX expression, where 
overexpression of PAX4 results in decreased glucagon+ cells (Spijker et al. 2013; 
Collombat et al. 2003; Gage et al. 2014). It is possible that HNF1A regulates PAX4 
expression via PAX4 promoter as it was shown previously that the human PAX4 
promoter can be bound by HNF1A (Smith et al. 2003) 
We found that our in vitro human HNF1A model validates many of the same gene 
targets found in rodent models, but in addition we find novel gene targets and mimic 
functional phenotypes observed in MODY3 patients. HNF1A mutant lines showed a 
tendency to have higher insulin secretion at basal glucose and lower insulin secretion at 
high glucose compared to controls (Figure 2.4A-C). It has been reported that neonatal 
MODY3 patients can counterintuitively present with hyperinsulinism at birth, which will 
then transition to diabetes later in life (Stanescu et al. 2012). Some of the novel HNF1A 
targets that we discovered could explain the diabetic phenotype of MODY3 individuals. 
Several of these genes are known causes of MODY such as PAX4 (Jo et al. 2011), 
RFX6 (Piccand et al. 2014), PDX1 (Sachdeva et al. 2009) and HNF4A (Arya et al. 2014) 
or know regulators of insulin secretion such as the insulin processing enzyme PCSK1 
(Stijnen et al. 2016), and ERO1LB which plays an essential role in proinsulin protein 
folding and maturation.  Mice deficient in Ero1lb are hyperglycemic with features of 
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impaired insulin secretion (Zito et al. 2010).  Another gene that could contribute to 
impaired insulin secretion is LDHA that is upregulated in HNF1A KO cell line as well as 
in type II diabetes (Marselli et al. 2010). LDHA is important for regulating cell metabolism 
and insulin secretion and when LDHA is upregulated it impacts metabolism and impairs 
insulin secretion (Ainscow et al. 2000). LDHA upregulation seems to be a common 
feature of diabetic beta cells as similar upregulation was observed in different diabetic 
models such as in GK rats (Homo-Delarche et al. 2006),  Sprague-Dawley rats (Jonas et 
al. 1999) and db/db mice (Ye et al. 2016) .  Overall, we present evidence suggesting that 
the lack of HNF1A leads to generation of abnormal beta-like cells with increases in 
glucagon expression and the beta-like cells deficient of HNF1A present defects in insulin 
secretion explained in part for deregulation of beta cell genes important for beta cell 
function and development.  
Data presented here also demonstrates that HNF1A is necessary for normal beta cell 
metabolism. Beta-like cells derived from HNF1A mutant stem cell lines display both 
decreased glycolysis and oxygen consumption (Figure 2.4D-H). Our genomics data 
suggest that HNF1A regulates genes at different steps of glycolysis pathway such as 
G6CP2 and LDHA, well known genes that regulate glycolysis, ATP production and 
insulin secretion (Li et al. 2009; Ainscow et al. 2000). Similar target genes related with 
glycolysis have been reported in HNF1A mouse model or by overexpressing a dominant 
negative form of HNF1A (Wang et al. 1998; Servitja et al. 2009). Surprisingly, when we 
examined oxygen consumption in beta-like cells, we found a defect in maximal 
respiration capacity only in the HNF1A HET but not in the KO cell lines. A complex gene 
regulatory network could explain HNF1A phenotype, both positive and negative inputs 
into genes required for proper cellular respiration and we hypothesized that such targets 
would be downregulated to a greater degree in HET versus KO genotypes. We found 
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one such target, LINKA, which displays a more severe downregulation of mRNA in HET 
over KO beta-like cells. When this lincRNA was disrupted by genome editing the 
mitochondrial defect from HNF1A HET beta-like cells was phenocopied.  Overall, these 
metabolic phenotypes are possible contributing mechanisms for both MODY3 as well as 
the known association between SNPs in the HNF1A gene and type II diabetes (Voight et 
al. 2010; Fuchsberger et al. 2016). 
The HNF1A target LINKA is a lncRNA present in primates but without homology in 
rodent genomes, making this a potential candidate to understand species-specific 
phenotypes relevant to human disease.  LINKA it is expressed in human pancreatic 
endocrine cell types at similar levels seen in in vitro derived beta-like cells as well as in 
human fetal pancreas (Figure 2.6D and S9A).  While the severity of the mitochondrial 
defect in LINKA null cells is similar to that of the HNF1A HET cells, it only partially 
mimics the other phenotypes seen in the HNF1A mutants suggesting that other HNF1A 
targets are also important for the full spectrum of phenotypes seen in MODY3 patients.  
How LINKA influences mitochondria respiration in unknown, but based on its function in 
other cell types, AKT signaling is a possible candidate pathway.  In cancer cell lines it 
has been shown that LINKA regulates AKT activation by acting as a scaffold to stabilize 
PIP3 and AKT interactions (Lin et al. 2017). Considering that AKT signaling has being 
reported to play an essential role in cellular respiration via the PI3K/mTOR pathways 
(Goo et al. 2012), we can speculate that loss of LINKA leads to diminished AKT 
activation and impaired mitochondrial function.  
 
	  62	  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Knockdown HNF1A in an immortalized human beta cell line EndoC-
BH1 present similar gene expression phenotypes seen in derived beta-like cell 
model. 
(A) Strategy to generated a knockout of HNF1A using a lentivirus specific to CRISPR-
CAS9  
(B) Lentivirus transduction in EndoC-BH1 carrying the CRISPR-CAS9 endonucleases 
(C) Flow cytometry quantification of HNF1A in EndoC-BH1 cell line after drug selection.  
(D-E) Gene expression of HNF1a target genes using sorted EndoC-BH1 HNF1A+ vs 
HNF1A- cells types.   
 
In addition, we found that LINKA is upregulated when beta cells were treated using beta 
cell stressors such as high glucose and IL-6 (Figure 2.6G).  This opens the possibility 
that this lincRNA could influence both type I and type II diabetes and be one potential 
mechanism for GWAS studies which have linked HNF1A SNPs to both of these 
diseases (Voight et al. 2010; Fuchsberger et al. 2016; Jerram & Leslie 2017).  The de-
repression of alpha cell genes seen in both the HNF1A and LINKA mutants is 
reminiscent of defects seen in diabetic islets and highlights how HNF1A/LINKA could 
influence this disease (Cinti et al. 2016; John et al. 2018; Spijker et al. 2015)   
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Overall, we showed evidence suggesting that HNF1A regulates beta cell function and 
cellular bioenergetics by regulating a subset of genes that contribute to the pathogenesis 
of MODY3 as well as its links to Type I and type II diabetes. Future studies will be 
essential to dissect the mechanism by which the human specific HNF1A target, LINKA, 
contributes to diabetes.  These studies also highlight the importance of human model 
systems, especially in cases where mouse models cannot mimic the human disease.      
 
 
 
 
 
 
 
Figure 2.9. LINCO1139 expression during pancreas development and diabetes. 
(A) LINC01139 (LINKA) is expressed during human pancreas development. Single cell 
RNAseq of human fetal pancreas at week 18 shows LINC01139 being expressed in beta 
and ductal cells. 
(B) LINC01139 expression using single cell RNA seq data seq of four different human 
samples: non diabetic (control), non diabetic young human (child), diabetes type 2 
human patient (T2D) and diabetes type 1 human patient (T1D). 
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CHAPTER 3. A DUAL REPORTER ENDOC-ΒH1 LINE FOR EFFICIENT 
QUANTIFICATION OF CALCIUM FLUX AND INSULIN SECRETION IN HUMAN Β-
CELL MODEL 
 
SUMMARY 
 
Understanding of the underlying pathogenesis of diabetes, especially pancreatic β-cell 
dysfunction, remains incomplete. As diabetes in all forms is highly genetic, though often 
multivariable, use of strategies such as genome-wide association studies (GWAS) in the 
past decade have helped discover candidate genes that are important in β-cell 
physiology and pathophysiology (Billings & Florez 2010; Kong et al. 2015; Fuchsberger 
et al. 2016). Understanding the roles of these candidate genes in β-cell function, 
however, has been challenging due to lack of suitable experimental models. These 
genes can be manipulated in rodent models, but this is time-consuming and expensive, 
and these models do not always recapitulate human physiology (King & Bowe 2015). In 
β-cell line models, functionality is assessed by quantification of secreted insulin 
measured using ELISA kits, which are costly and labor-intensive (Nell et al. 1985). 
Another method to measure β-cell function is the quantification of calcium flux, but this 
method is technically challenging (Gandasi et al. 2017; Rorsman et al. 2012) 
 
We have generated a set of cellular tools in a human β-cell line with glucose-responsive 
insulin secretion that allows for the efficient and inexpensive characterization of 
candidate genes in β-cell physiology. We found that lentiviral infection of the EndoC-βH1 
cell line is efficient and was able to generate a dual reporter cell line expressing both an 
insulin-Gaussian luciferase fusion protein and the protein calcium sensor, GCaMP6s. 
The resulting stable cell line is ideal for facilitating the quantification of insulin secretion 
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and calcium flux in response to stimuli in both static and perfusion systems. We can then 
further manipulate this cell line using lentiviral vectors carrying the CRISPR-Cas9 
system to generate β-cells carrying candidate gene mutations.  The generation of mutant 
cell lines with CRISPR-Cas9 was performed by using a single gRNA to achieve 90% 
efficiency knock-down of PDX1, Insulin or HNF1α protein. Using the insulin-luciferase 
fusion protein and GCaMP6s, we show that the PDX1 mutant β-cells do not exhibit 
changes in calcium and fail to secrete insulin when stimulated with high glucose. 
Furthermore, we show that the PDX1 mutant β-cells exhibit differential gene expression 
of critical targets of β-cell functionality and identity including decreased MAFA and 
NKX6.1 and increased GLUCAGON mRNA transcript levels. 
 
METHODS 
 
Cell culture. 
The EndoC-βH1 cell line was grown according to Ravassard et. al. 2011. Plates were 
coated with matrigel 100µg/mL and human fibronectin 2 µg/mL (Sigma) in DMEM low-
glucose (Gibco). Cells were cultured in DMEM low-glucose supplemented with 10% BSA 
fraction V (Sigma), 50µM 2-mercaptoethanol, 10mM nicotinamide (Sigma), 5.5µg/mL 
transferrin (Roche Diagnostics), 6.7ng/mL selenite (Sigma). Cells were split once every 
seven days using 0.25% trypsin and replated at a 1:2 ratio. 
 
Cloning and lentivirus 
The GCaMP6s plasmid was acquired from Addgene plasmid number 40753 and the 
Insulin-Gaussia-luciferase construct was a gift from Dr. Pei Wang from UT Health San 
Antonio. Transgenes were cloned into a lentivirus vector using In-Fusion cloning kit 
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(Clontech). The expression of the transgenes driven by rat insulin promoter (RIP) 
promoter was donated by Christopher Newgard.  The CRISPR-Cas9 lentivirus vector 
was purchased from Addgene (Plasmid #52961); using In-Fusion cloning kit (Clonthech), 
the EFS promoter was replaced by the RIP and the BsmBI restriction sites were 
changed for HpaI to facilitate further cloning of the plasmid. Cloning the gRNAs into the 
lentivirus vector was performed as described in Mali et. al. 2013 
 
Lentiviruses were generated by mixing lentiviral backbone packaging plasmids, VSVG, 
TAT, REV and HMGP2 at a ratio of 0.2: 0.2: 0.2: 0.3. A total of 24.8 µg of the packaging 
plasmids were mixed with 24.8 µg of the transgene plasmid and transfected into 
HEK293 cells on a 100mm dish using 2.5M CaCl2 and 2x HEPES. The supernatant was 
collected for two days and spun down at 19,500rpm for 90 min at 4°C. The viral pellet 
was resuspended in 500µL HEK293 media.  
 
Virus infection and drug selection. 
5 x106 cells were plated on a 6-well plate coated with matrigel and fibronectin. 24 hours 
after seeding, virus infection was performed by incubating cells with 2mL of the EndoC-
βH1 media, 40µL of concentrated lentivirus and 2µL of polybrene (Millipore) overnight. 
The following day, the infected cells were washed twice using IMDM media and re-fed 
with normal EndoC-βH1 media. 48 hours after infection, 2µg/mL puromycin was added 
to the EndoC-βH1 media for one week. After 7 days of drug selection, cells were fed for 
2 days with EndoC-βH1 media without puromycin. All experiments were performed 
following drug selection. 
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GSIS perfusion assay and Calcium imaging 
50,000 cells per well were seeded in a 96-well lumox multiwell plate (SARSTEDT) and 
each well was transferred to the imaging chamber of a perfusion system. Input perfusion 
solution was supplied using a high-flow peristaltic pump (Instechlabs). Perfusion solution 
consist in Krebs-Ringer Bicarbonate HEPES Buffer (KRBH) 115 mmol/liter NaCl, 24 
mmol/liter NaHCO3, 5 mmol/liter KCl, 1 mmol/liter MgCl2, 2.5 mmol/liter CaCl2, 10mM 
HEPES, pH 7.4) prewarm at 37°C. Cells were incubated for 45 minutes at 37°C 5% CO2 
incubator. To perform glucose-stimulated insulin secretion (GSIS) and calcium flux 
imaging, cells were transfer to the perfusion chamber where cells were perfused with a 
constant flow rate of 350µL of KRBH for 30 minutes at 37°C then input prefusion solution 
was changed to 2mM D-glucose KRBH for 15 minutes followed by 30 minutes in 20mM 
D-glucose KRBH and finally 10 minutes in 30mM KCl KRBH. To quantify insulin 
secretion using the fusion protein preproinsulin-Gaussia luciferase, 50µL of perfused 
media per time-point (per min) was measured using the Pierce Gaussia luciferase flash 
assay kit (Life technologies). Collection of output perfused solution start 20min after 
KRBH incubated in the chamber and it was collected into a 96-well plate every minute 
using a Gilson 203B fraction collector. A Leica 8900 series fluorescence microscope was 
used for live cell imaging. Images were taken every 10 seconds using a GFP channel 
and processing imaging (GFP fluorescence intensity over time) was perfomed using the 
software Leica Application Suite X. Results are presented as GFP mean fluorescence 
intensity of the whole field versus time. 
 
Static GSIS and C-Peptide ELISA 
Cells were plated in a 6-well plate (~1.5X106 cells per well). 48 hours after adherent cells 
were used to perform GSIS. Cells were washed twice very gently using KRBH buffer. 
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Before to start GSIS, cells were starved for 60min by leaving cells with 2ml of KRBH 
buffer and place in incubator (37°C, 5% CO2). After starvation, KRBH buffer was 
removed and cell were incubated using 1ml of 2mM D-Glucose KRBH buffer and 
incubate for 30min in incubator (37°C, 5% CO2, supernatant was collected and then cells 
were finally incubated using 1ml of 20mM D-Glucose KRBH for 30min in incubator 
(37°C, 5% CO2) and supernatant was collected. Supernatant was used to performed C-
Peptide quantification using ultrasensitive C-Peptide ELISA Kit from Mercomedia. To 
quantify insulin secretion via Gaussia luciferase, supernantant from GSIS was used to 
was measured luciferase using the Pierce Gaussia luciferase flash assay kit (Life 
technologies). 
 
Staining, flow cytometry, and cell sorting.  
Cells were harvest and fixed in 1.6% PFA for 30 minutes at 37°C. Intracellular staining 
was performed by using 1x saponin to permeabilize the membrane and incubating in 
primary antibody for 30 minutes followed by secondary antibody for 30 minutes. 
Samples were resuspended in FACS buffer and analyzed using a CANTOS BD flow 
cytometer. In order to perform cell sorting, cells were fixed using 4% PFA for 30 minutes. 
Cells were stained the following day, sorted by FACSAria II and collected for RNA 
isolation ((Hrvatin et al. 2014)). A list of the antibodies used can be found in tables 3.1 
and 3.2. 
 
RNA isolation and qRT-PCR 
In order to extract RNA from fixed cells, we followed the MARIS protocol ((Hrvatin et al. 
2014)). RNA from sorted samples was isolated using the RecoverAll™ Total Nucleic 
Acid Isolation Kit for FFPE (Life Technologies/Ambion). cDNA was made using random 
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hexamers and Superscript II Reverse Transcriptase (Invitrogen). Quantification of 
relative mRNA was performed in triplicate using SYBR-GreenER qPCR Master Mix 
(Roche).  A list of the primers used for qRT-PCR can be found in table 3.   
 
Statistical Analysis 
Statistical analysis were perfomed using GraphPad Prism 6 software. The results are 
expressed as the mean ± standard error of the mean. An unpaired two-tailed Student’s t-
test for groups with equal variance were performed to determine p values. In figures * 
P<0.05.  
 
List of primers for qRT-PCR and antibodies 
 
 
 
 
 
 
 
 
 
 
 
ANTIBODY COMPANY CATALOG ANTIBODY COMPANY CATALOG
HNF1A Cell)Signaling D7Z2Q Goat7anti7Rabbit)IgG7)Phycoerythrin) Jackson)Immunoresearch) 11171167144
PDX1 R&D BAF2419 Goat7anti7mouse)IgG17)Alexa647 Jackson)Immunoresearch) 11571157205
C7PEPTIDE Cell)Signaling 4593S Donkey)Anti7Rabbit)IgG7647 Jackson)Immunoresearch) 711-606-152
INSULIN Sigma I2018 Streptavidin7)Alexa647 Invitrogen) S32357
Primary3Antibodies Secondary3Antibodies
Gene$ FORWARD REVERSE
GCG TTCCCAGAAGAGGTCGCCATTGTT CAACCAGTTTATAAAGTCCCTGGCGG
NKX6.1 AAGAAGCACGCTGCCGAGATG CCGAGTTGGGATCCAGAGGCTTATT
MAFA TGCAGCAGCGGCACATTCT% CGCCAGCTTCTCGTATTTCTCCTTGT
INSULIN TTTGTGAACCAACACCTGTGCGG GCGGGTCTTGGGTGTGTAGAAGAA
AKT GACAATGACTACGGCCGTGC AGCTTCTCATGGTCCTGG
TBP TTGCTGAGAAGAGTGTGCTGGAGATG CGTAAGGTGGCAGGCTGTTGTT
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RESULTS 
 
Insulin secretion and calcium flux can be quantified in the human β-cell line 
EndoC-βH1 expressing an insulin-luciferase fusion protein and GCaMP6s.  
  
To more efficiently measure calcium levels and insulin secretion in the EndoC-βH1 cell 
line, we cloned the protein calcium sensor GCaMP6s and an insulin-Gaussia luciferase 
fusion protein into a single lentiviral vector. These transgenes are driven by the rat 
insulin promoter (RIP), allowing robust expression in these insulin-producing cells 
(Figure 3.1A). The transduction efficiency was approximately 95%. To examine the 
sensitivity of the GCaMP6s calcium reporter, we measured GFP fluorescence intensity 
in response to different stimuli. Under basal conditions in the absence of glucose, GFP 
fluorescence intensity is low. This intensity increases 2.5-3 fold when cells are incubated 
in 20mM glucose as expected. Subsequent exposure to 30mM KCl to fully depolarize 
the cells causes GFP fluorescence intensity to increase 6-fold over basal levels. 
Importantly, GFP fluorescence intensity returns to basal levels upon pre-incubation with 
KRBH buffer alone, showing that the cells can recover to baseline after stimulation 
(Figure 3.1B and 3.1E). 
 
The insulin-luciferase fusion protein has been previously shown to be packaged into the 
endogenous insulin vesicles and secreted from the cell at a 1:1 ratio with insulin upon 
stimulation with glucose and KCl (Kalwat et al. 2016; Burns et al. 2015). To determine if 
the insulin-luciferase could be used as a faster and inexpensive surrogate for insulin 
secretion, we performed glucose-stimulated insulin secretion (GSIS) assays and 
compared the levels of luciferase and insulin secreted into the media. Cells were 
incubated in basal glucose (D-glucose-2 mM) for 15 minutes followed by incubation in 
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high glucose (D-glucose-20 mM) for 30 minutes. Media was collected after each 
incubation and assayed for luciferase and C-peptide content. Both C-peptide and 
luciferase levels increased 2.5-3.5 fold under stimulated conditions compared with basal 
levels (Figure 3.1C and 3.1D). These results show that the luciferase assay is highly 
sensitive and can be used as a reliable readout for insulin secretion even when samples 
are diluted 100-fold (Figure 3.1C). Furthermore, we validated the use of both of these 
reporter tools in a perfusion set-up, allowing for an inexpensive and rapid way to 
measure calcium levels and insulin secretion in the same cultures and at many time 
points under different stimuli (Figure 3.1E). 
 
CRISPR-Cas9 presents an efficient way to knockout genes in EndoC-βH1 cells.  
 
These reporter tools can be useful in the investigation of the roles of gene targets in β-
cell function, mutations in gene candidates would have to be quickly introduced into the 
EndoC-βH1 cell line. Unfortunately, EndoC-βH1 cells have a doubling time of 
approximately one week, making the generation of clonal lines difficult. Therefore, we 
tested the efficiency of the CRISPR-Cas9 system in bulk cultures. We used the lentivirus 
backbone V2-CRISPR (Sanjana et al. 2014), adding a construct using the RIP to drive 
the expression of Cas9 and puromycin genes. The non-clonal EndoC-βH1 cells were 
transduced with this lentivirus, and the non-transduced cells were eliminated using 
puromycin selection for seven days after viral transduction (Figure 3.2A). ). To test the 
efficiency of this technique, we choose three genes of interest: INSULIN (INS), PDX1, 
and HNF1A. For each gene, we selected two gRNAs and cloned each into the lentiviral 
backbone (Figure 3.2B). After seven days of puromycin selection, cells were harvested, 
and the knockout efficiency was quantified using flow cytometry (Figure 3.2C).  Though 
knockout ability varied, the robust knockout was achieved in all cases: INS and HNF1A 
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showed approximately ~90% of cells with a complete absence of protein, while PDX1 
had 75% (Figure 3.2D) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Proof of principle engineering a dual tool to measure insulin secretion 
and calcium flux in human pancreatic cell line. 
A. Schematic representation of lentivirus construct carrying GCamp6 and preproinsulin-
luciferase transgenes being driven by the rat insulin promoter (RIP). 
B. Transduced cells presented changes of GFP intensity in response to different stimuli 
glucose and KCl  
C. Luciferase assay sensitivity, serial dilution showed the limiting dilution to use the 
assay.  
D. Stimulation index compared using Luciferase assay and human C-Peptide ELISA 
demonstrating the highly sensitivity of the luciferase assay.  
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E.Perfusion of transgenic line allow to follow calcium flux by GFP intensity and insulin 
secretion by luciferase signal. 
     
Figure 3.2. Overview and validation of the strategy to knockout genes using a 
immortalized pancreatic beta cell line EndoC-βH1. A. The V2  lentivirus construct 
modified using a RIP promoter to drive CAS9 expression and a HpaI restriction site to 
clone a desire gRNA and puromycin drug selection to enrich for cells with V2 lentivirus. 
B. gRNAs used per gene, the position represented the localization of the gRNA in each 
exon. C. Flow cytometry analysis using insulin CRISPR to calculate the efficiency of 
Knock-down. D. Statistical quantification of Knock-down efficiency per gRNA per gene, 
efficiency was calculated by FACS. 
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further characterized the PDX1 knockout cells. Using the cellular tools in the perfusion 
system, PDX1- cells showed a failure in calcium flux and insulin secretion in response to 
stimulation with 20mM glucose as measured by fluorescence intensity and luciferase 
content. However, upon depolarization with KCl, there is an increase in calcium and 
insulin secretion, albeit lower than that observed in the controls (Figure 3.3C and 3.1E). 
To help understand the role of PDX1 in the EndoC-βH1 cell model, we sorted for those 
cells lacking PDX1 protein after lentiviral infection using intracellular flow cytometry 
(PDX1-1) we compared the expression of critical genes for β cell identity, function and 
apoptosis in sorted cells with persistent PDX1 expression after drug selection (PDX1+) 
and those without PDX1 expression (PDX1-) (Figure 3.3A). Interestingly, loss of PDX1 
led to downregulation of INS, MAFA, and NKX6.1 mRNA but increased GCG mRNA 
(Figure 3.3B), consistent with PDX1 known role as a master regulator of β-cell identity. 
 
 
DISCUSSION 
 
In this report, we have described a set of tools for use in a human β-cell line that allows 
for the detection of insulin secretion using Gaussia luciferase and calcium flux using 
GCaMP6s. We have shown that luciferase and insulin levels correlate following 
stimulation with glucose and KCl.  In the same cultures, we can monitor calcium flux 
using the protein calcium sensor GCaMP6s by quantifying changes in GFP fluorescence 
intensity that reflect the amount of calcium present in the cell (Cai et al. 2014; Yang et al. 
2018; Partridge 2015). The generation of this cell line presents an efficient means of 
quantifying calcium flux and insulin secretion in a human β-cell line.  It is also 
approximately ten times less expensive compared with regular commercial insulin or c-
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peptide ELISAs, making this system amenable to high throughput screening efforts. 
Additionally, we demonstrate that the dual reporter cell line can be used to track calcium 
flux and insulin secretion in a perfusion system. In a single culture, we see calcium flux 
and insulin secretion increase in succession in response to 20 mM glucose, which 
recapitulates what has been long described by other groups using perfusion models of 
rodent and human islets (Kaminski et al. 2012; Rountree et al. 2014; Sweet & Gilbert 
2006).  
 
Furthermore, we demonstrate that this dual reporter cell line can be used to interrogate 
the role of genes critical for β-cell function by using CRISPR-CAS9 in lentiviral vectors to 
produce mutant lines. Despite the slow growth rate of the EndoC-βH1 cells, which only 
double once every seven days, and their inability to form clonal colonies, we can 
knockout the expression of target genes with 70-95% efficiency. Using the CRISPR-
Cas9 system, we were able to characterize the role of PDX1 in the EndoC-βH1 cell line. 
Lack of  PDX1 results in the loss of the β-cell identity as shown by increasing GCG 
expression and decreasing INS, NKX6.1, and MAFA expression. Additionally, it also 
leads to impairment in calcium flux and insulin secretion upon stimulation with 20mM 
glucose (Gao et al. 2014; Gutiérrez et al. 2017; Fujitani 2017; Ahlgren et al. 1998) 
Together, these findings demonstrate that the use of the dual reporter EndoC-βH1 cell 
line offers a useful and rapid human model to study candidate genes related to β-cell 
function and their potential role in diabetes. Furthermore, these tools could be easily 
adapted and applied in drug screening platforms for subsequent translational 
applications. 
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Figure 3.3. Loss of PDX1 in EndoC-BH1 impairs insulin secretion and calcium flux 
where a set of important genes for beta cell function is downregulated.  
A. EndoC-BH1 cells lentivirus infected were stained using a PDX1 antibody and sorted 
for PDX1+ and PDX1- to further compared gene expression differences between the two 
populations.  
B. qRT-PCR to quantify relative gene expression comparing PDX1+ and PDX1- 
populations.  
C. EndoC-BH1 cells lentivirus infected were perfused using different stimuli in order to 
quantify insulin secretion (luciferase) and calcium flux (GCamp6). 
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CHAPTER 4. SUMMARY AND FUTURE DIRECTIONS 
 
This thesis focused on the generation of a human model of MODY3, to understand the 
pathogenesis of monogenic diabetes caused by the deficiency of HNF1A in vitro. We 
used genetically modified human PSCs to derive beta-like cells using the most advanced 
in vitro differentiation protocol (Rezania, Riedel, et al. 2014). Our findings suggest that 
HNF1A plays an important role in β-cell development, insulin secretion, cellular 
respiration, and impacts multiple genes important in beta cell function. In this chapter, 
we want to discuss different open questions and possible approaches that can contribute 
to a better understanding of the role of HNF1A in derived beta-like cells. 
 
4.1 HNF1A as a transcriptional regulator of endocrine cell fate 
Data analysis derived from the genome profiling of HNF1A in beta-like cells showed that 
HNF1A regulated the gene expression of more than 501 genes. However, are those 
genes direct or indirect targets of HNF1A? Does HNF1A regulate genes related to alpha 
cell program during pancreas differentiation?  
To answer those two questions, first, it will be necessary to perform a CHIP-seq assay at 
two different time points of the differentiation. At pancreatic progenitor 2 (PP2) and beta 
like cell stage. PP2 is the time point where expression of genes necessary for endocrine 
cell fate occurs and at the second time point cell fate has occurred, but we can still look 
if HNF1A is regulating candidate genes. The data analysis will focus on looking at PAX4 
regulation at the PP2 stage. Our data suggest that the lack of HNF1A results in 
decreased expression of PAX4, leading to increased ARX, which could explain the 
upregulation of GLUCAGON and GHRELIN.  
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In the case that there is evidence of HNF1A regulating PAX4 via physical interaction, 
then deletions in the regulatory region of PAX4 for binding sites for HNF1A, using 
CRISPR-CAS9 nucleases will corroborate the physical interaction. ESCs carrying 
deletions of the HNF1A binding site in the PAX4 regulatory region can be differentiated 
to demonstrate the contribution of this specific gene into the HNF1A phenotype. 
The next question is to see if HNF1A or any other downstream target is sufficient to 
rescue HNF1A phenotypes observed, such as the increase of GLUCAGON in HNF1A 
KO cell line. Knowing the direct targets of HNF1A, we can overexpress HNF1A using 
lentivirus vectors at the PP2 stage or prior and use qRT-PCR to quantify if HNF1A 
targets genes can be rescued. Additionally, flow cytometry assays could be used to 
check changes in the hormone cell population composition with or without 
overexpression of HNF1A. 
Using the same example of experiments described above, multiple candidate genes can 
be interrogated to see their contribution to the HNF1A phenotype and elucidate a 
pathway by which HNF1A works as a repressor or regulator of endocrine cell fate. 
 
4.2 Insulin secretion using in-vivo maturation model  
We presented evidence that HNF1A HET and KO cell lines present impaired insulin 
secretion in vitro, but we observed that those cell lines still secreted insulin at lower 
glucose levels compared to WT cell line. The next question to be answered is to see if 
HNF1A mutant lines can rescue diabetes in vivo. Different groups have shown that 
derived beta-like cells can be transplanted in the kidney capsule of the mouse and after 
a couple of months human C-Peptide or insulin can be detected in the mouse 
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bloodstream meaning that the transplanted cells successfully engrafted in the kidney. 
Then diabetes is induced chemically in the mouse by injecting streptozotocin (STZ) and 
rapidly will destroy mouse beta cells (Nir et al. 2007; Faleo et al. 2017; Cantarelli et al. 
2013). The expected result is that HNF1A mutant cell lines do not rescue diabetes. If 
that were the case, the next future experiment would be to interrogate the capacity of the 
remaining insulin granules to ameliorate diabetes by using different drugs such as 
sulfonylureas, which depolarized beta cell membrane. 
 
4.3 HNF1A regulating metabolic stress  
It has been suggested that pathogenesis of diabetes type 2 could be explained by 
chronic stress metabolism leading to accumulation of oxidative stress, reactive oxygen 
species, dedifferentiation and cell exhaustion (Swisa et al. 2017; Piccand et al. 2014; 
Cantley & Biden 2013; Cinti et al. 2016). HNF1A mutant lines present deregulation in cell 
metabolism, cell respiration and multiple genes essential in these pathways. 
Cellular respiration plays an essential role in the generation of ATP, affecting calcium 
influx, which is known to regulate insulin secretion (Komatsu et al. 2013). Then the next 
question is to address the role of HNF1A beta cell metabolic pathway related with ATP 
production and calcium flux. We hypothesize that HNF1A is necessary for ATP 
production to regulate calcium flux and insulin secretion.  
To test this hypothesis, it will require isolation of beta-like cells from the three genotypes 
of HNF1A and perform two critical experiments. First, establish the ATP production of 
beta-like cells in lower and high glucose. Second, perform a perfusion assay to quantify 
calcium flux dynamics using lower and higher glucose. This experiment will help us to 
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understand the dynamic of ATP production and calcium flux in beta-like cells deficient for 
HNF1A and this data could be correlated with insulin secretion. The expected result is 
that cells deficient for HNF1A present lower ATP production and calcium flux. 
Moreover, Diabetes type 2 samples present upregulation of LDHA resulting in lower 
insulin secretion, lower ATP production and cell dedifferentiation to a transitory beta-like 
cell (Ainscow et al. 2000; Cantley & Biden 2013). Given that HNF1A KO cell lines also 
present higher upregulation of LDHA, then we would look into the contribution of this 
gene into HNF1A and diabetes type 2. This will require transduction of shRNA specific 
for LDHA into HNF1A KO cell line to later quantify insulin secretion, ATP production and 
calcium flux comparing HNF1A KO transformed cells with LDHA-shRNA versus mock-
shRNA.    
Finally, another phenotype that could explain the link between HNF1A and diabetes 
phenotype is related to beta cell exhaustion. It is known that chronic stress leads to high 
metabolic demand and the cells burn out because they can not keep up with the high 
metabolic rate, overall resulting in decreased cell functionality. Our data suggested that 
deficiency in HNF1A does not impair the generation of insulin-positive cells, but the cells 
presented an inadequate response to glucose stimulation and lower metabolism. It is 
possible that the lack of HNF1A contributes to cell exhaustion and the reason why we 
can see the phenotype is because the cells are cultured in a stressful condition with non-
physiological levels of glucose, contributing to chronic stress resulting in cell exhaustion. 
The hypothesis is that HNF1A mutants present impaired insulin secretion due to cell 
exhaustion. The experiment to test that question will consist in culturing cells in vitro 
using lower glucose under physiological levels 5.5mM glucose versus 20mM glucose 
and perform an insulin secretion assay.  An in vivo experiment could be performed to 
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elucidate the phenotype under physiological conditions. For this purpose, HNF1A mutant 
lines and control will be transplanted under the kidney capsule of different NOD-SCID 
mice, and the mice can be kept under two different diets, standard diet (control) versus 
high-fat diet (cell exhaustion) and perform insulin secretion after mice have been treated 
with STZ. If our hypothesis is correct, cells kept under high glucose levels and animals 
under high-calorie intake will show impaired insulin secretion compared to controls. 
 
4.4 HNF1A acts as an antioxidant to protect beta cells to ROS accumulation. 
There is evidence suggesting that part of the diabetes type 2 phenotype involves lipid 
and glucose toxicity as a result of the high cell metabolism demand resulting in 
accumulation of oxidative stress producing and accumulating reactive oxygen species 
(ROS). Additionally, diabetic islets present low antioxidant capacity resulting in cell 
toxicity and eventually cell death (Robertson et al. 2004; Robertson & Harmon 2009; Lei 
& Vatamaniuk 2011; Miki et al. 2018). The Metallothionein gene family plays a role as an 
antioxidant, and our data showed that a large number of Metallothionein genes are 
downregulated in HNF1A mutant cells. It will worth to explore how downregulation of 
these family genes contributes to the HNF1A phenotype. We hypothesize that the lack of 
HNF1A leads to increase of ROS accumulation due to deregulation of Metallothionein 
genes. To test this hypothesis, HNF1A mutant and WT will incubate in media with 
inducing ROS production such as H2O2 or high glucose, after which they will be stained 
with a ROS indicator dye and quantified as ROS positive cells using flow cytometry 
assay. In the case that the HNF1A mutant cell accumulates ROS, the following 
experiment would be to explore the potential to overexpress different Metallothionein 
genes using a lentivirus approach to see if ROS levels decrease under overexpression.  
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4.5 LINKA as a mediator to regulate oxygen consumption and beta cell stress via AKT 
signaling 
We found a novel long non-coding RNA (LINKA), which upon ablation leads to lower 
mitochondrial oxygen consumption in beta-like cells. We did not find a specific 
downstream gene target of HNF1A that could explain how LINKA regulates oxygen 
consumption. A future experiment to understand the relationship between LINKA and 
cellular respiration will require to perform a genome profiling of derived beta-like cells 
using WT and LINKA mutant cell lines to explore differential gene expression between 
the two genotypes and look for candidate genes that could explain this phenotype.  
The candidate genes could be overexpressed in LINKA mutant lines using lentivirus 
vectors then cells with or without lentivirus will be interrogated for oxygen consumption. 
The expected result is that we can find a gene that rescues the phenotype. Similarly, the 
genes that have the potential to rescue oxygen consumption in the LINKA mutant line 
can be used in HNF1A-HET cell lines to start elucidating the epistatic interaction 
between HNF1A-LINKA and downstream target genes. 
Moreover, LINKA plays an essential role in regulating AKT phosphorylation (Lin et al. 
2017). AKT regulates diverse signal transduction pathways important for beta cell 
related to cell proliferation and cell protection (Bernal-Mizrachi et al. 2004; Bernal-
mizrachi et al. 2001). We showed evidence that LINKA is upregulated in the presence of 
different insults for the beta cells which might indicate that LINKA could work as a stress 
sensor potentially through the AKT pathway. Future directions will be related to 
addressing the role of LINKA in derived beta-like cells and its relationship with cell 
protection via the AKT pathway. The hypothesis is that LINKA protects beta-like cells 
from apoptosis under glucose or lipotoxicity via the AKT pathway. The future experiment 
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consists in using WT and LINKA mutant lines and exposes them to glucose and lipid 
toxicity reagents to see the state of AKT phosphorylation in residues Ser473 or Thr308. 
The comparison of both genotypes can be performed and also the quantification of cell 
stress signals like cell viability and apoptosis via Annexin V, Caspase 3 and 7-AAD. 
Additionally, if our hypothesis is correct, these experiments will open the possibility to 
explore different downstream targets of AKT signaling like mTOR phosphorylation, which 
has direct implications in cellular respiration (Morita et al. 2013; Schieke et al. 2006). 
Besides, overexpression of LINKA will determine if LINKA is sufficient to rescue cellular 
respiration phenotype and gene expression of downstream target genes. 
 
4.6 Does HNF1A or LINKA contribute to beta cell development?  
The HNF1A phenotypes described here belong to ESCs that carry HNF1A mutations 
and then are matured into beta-like cells. These phenotypes are a consequence of beta 
cell development. To differentiate which phenotypes are specific to developmental 
defects and beta cell intrinsic, further experiments will be necessary. It will be required to 
generate a tissue-specific gene knockout ESC line by using the Cre/LoxP system 
(Magnuson & Osipovich 2013; Du et al. 2009).  The HNF1A gene will be flanked using 
loxP sites, and the Cre recombinase gene will be a heterozygous knock-in in the insulin 
locus. Using this strategy, in theory, every cell that expresses insulin will be deficient for 
HNF1A. This cell line will be useful to determine the HNF1A beta cell intrinsic 
phenotype.  
To summarize, the generation of the MODY3 human model using ESCs facilitates the 
interrogation of HNF1A in beta-like cells. This model gives the opportunity to dissect the 
molecular mechanism of the disease pathogenesis-related with the monogenic diabetes 
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MODY3. The impact of this research could help us to understand beta cell function 
related with diabetes but also open the opportunities to use these cell types to consider 
drug screenings to postulate new compounds that improve beta cell functionality or beta 
cell protection which could be translated in better treatments for patients who have 
diabetes. 
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